BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Du S, Cai J, Wang J, Shen X. Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. Cancer Manag Res 2020;12:13161-71. [PMID: 33376407 DOI: 10.2147/CMAR.S284115] [Reference Citation Analysis]
2 Dhillon H, Mamidi S, McClean P, Reindl KM. Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathways. J Med Food 2016;19:578-85. [PMID: 27119744 DOI: 10.1089/jmf.2015.0152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ray P, Nair G, Ghosh A, Banerjee S, Golovko MY, Banerjee SK, Reindl KM, Mallik S, Quadir M. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. J Cell Commun Signal 2019;13:407-20. [PMID: 30915617 DOI: 10.1007/s12079-019-00514-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
4 Kim SY, Park S, Yoo S, Rho JK, Jun ES, Chang S, Kim KK, Kim SC, Kim I. Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Oncotarget 2017;8:61057-71. [PMID: 28977846 DOI: 10.18632/oncotarget.17841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Lacomb JF, Plenker D, Tiriac H, Bucobo JC, D'souza LS, Khokhar AS, Patel H, Channer B, Joseph D, Wu M, Tuveson DA, Li E, Buscaglia JM. Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. Clin Gastroenterol Hepatol 2021;19:845-7. [PMID: 32119924 DOI: 10.1016/j.cgh.2020.02.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 2016;96:47-62. [PMID: 27135716 DOI: 10.1016/j.biomaterials.2016.04.010] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 13.7] [Reference Citation Analysis]
7 Nouso K, Amano M, Ito YM, Miyahara K, Morimoto Y, Kato H, Tsutsumi K, Tomoda T, Yamamoto N, Nakamura S, Kobayashi S, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Nakahara T, Nishimura S, Yamamoto K. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol 2013;48:1171-9. [DOI: 10.1007/s00535-012-0732-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
8 Zhao C, Yang S, Lin L, Weng S, Liu Q, Liu A, Lin X. Chronocoulometric biosensor for K-ras point mutation detection based on E. coli DNA ligase and AuNPs amplification effects. Sensors and Actuators B: Chemical 2016;223:946-51. [DOI: 10.1016/j.snb.2014.06.091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63. [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539] [Cited by in Crossref: 131] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
10 Funel N. The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors? Epigenomics 2015;7:333-5. [DOI: 10.2217/epi.15.19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Bekeschus S, Freund E, Spadola C, Privat-Maldonado A, Hackbarth C, Bogaerts A, Schmidt A, Wende K, Weltmann KD, von Woedtke T, Heidecke CD, Partecke LI, Käding A. Risk Assessment of kINPen Plasma Treatment of Four Human Pancreatic Cancer Cell Lines with Respect to Metastasis. Cancers (Basel) 2019;11:E1237. [PMID: 31450811 DOI: 10.3390/cancers11091237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
12 Chakrabarty AM, Bernardes N, Fialho AM. Bacterial proteins and peptides in cancer therapy: today and tomorrow. Bioengineered 2014;5:234-42. [PMID: 24875003 DOI: 10.4161/bioe.29266] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
13 Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, Hessmann E, Gaedcke J, Güthle M, Zenke M, Hartmann D, von Figura G, Weissinger SE, Rudolph KL, Möller P, Lennerz JK, Seufferlein T, Wagner M, Kleger A. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun 2015;6:7677. [PMID: 26220524 DOI: 10.1038/ncomms8677] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
14 Yang D, Tang Y, Fu H, Xu J, Hu Z, Zhang Y, Cai Q. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling. Biochem Biophys Res Commun 2018;505:215-21. [PMID: 30243721 DOI: 10.1016/j.bbrc.2018.09.061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
15 O’Neill CB, Atoria CL, O’Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118:5132-5139. [PMID: 22415469 DOI: 10.1002/cncr.27490] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
16 Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32. [PMID: 31375338 DOI: 10.1016/j.hpb.2019.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
17 Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011;12:1641-1652. [PMID: 22026922 DOI: 10.2217/pgs.11.109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
18 Okura R, Fujihara S, Iwama H, Morishita A, Chiyo T, Watanabe M, Hirose K, Kobayashi K, Fujimori T, Kato K, Kamada H, Kobara H, Mori H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T. MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells. Oncol Lett 2018;15:407-14. [PMID: 29387226 DOI: 10.3892/ol.2017.7316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
19 De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol 2018;233:8482-98. [PMID: 29797573 DOI: 10.1002/jcp.26786] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
20 Ding J, Li H, Liu Y, Xie Y, Yu J, Sun H, Xiao D, Zhou Y, Bao L, Wang H, Gao C. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:698302. [PMID: 34804914 DOI: 10.3389/fonc.2021.698302] [Reference Citation Analysis]
21 Cheng TM, Murad YM, Chang CC, Yang MC, Baral TN, Cowan A, Tseng SH, Wong A, Mackenzie R, Shieh DB. Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells. Eur J Cancer. 2014;50:713-721. [PMID: 22918079 DOI: 10.1016/j.ejca.2012.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ji L, Gong C, Ge L, Song L, Chen F, Jin C, Zhu H, Zhou G. Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma. Exp Ther Med 2017;13:551-9. [PMID: 28352330 DOI: 10.3892/etm.2016.3968] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tummers WS, Willmann JK, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. Pancreas 2018;47:675-89. [PMID: 29894417 DOI: 10.1097/MPA.0000000000001075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
24 Yalcin M, Lin H, Sudha T, Bharali DJ, Meng R, Tang H, Davis FB, Stain SC, Davis PJ, Mousa SA. Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles. HORM CANC 2013;4:176-85. [DOI: 10.1007/s12672-013-0137-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
25 Imamura T, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2016; 22(25): 5627-5641 [PMID: 27433079 DOI: 10.3748/wjg.v22.i25.5627] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
26 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
27 Kopantsev EP, Kostina MB, Grankina EV, Kopantseva MR, Egorov VI, Sverdlov ED. Expression of Therapeutic Gene FCU1 Sensitizes Pancreatic Cancer Cells to 5-Fluorocytosine and Enhances the Cytotoxic Effect of 5-Fluorouracil. Bull Exp Biol Med 2016;161:808-10. [PMID: 27783293 DOI: 10.1007/s10517-016-3517-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Łukaszewicz-Zając M, Gryko M, Mroczko B. The role of selected chemokines and their specific receptors in pancreatic cancer. Int J Biol Markers 2018;33:141-7. [PMID: 29799354 DOI: 10.1177/1724600817753094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
29 Brandi G, Tavolari S, Guarnieri T, Di Marco M, Paterini P, Macchini M, Di Girolamo S, Papi A, De Rosa F, Biasco G. Antiprotease Strategy in Pancreatic Cancer Treatment: Emergence From a Preclinical Study. Pancreas 2014;43:53-63. [DOI: 10.1097/mpa.0b013e3182a6486e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
30 Wei W, Sun HH, Li N, Li HY, Li X, Li Q, Shen XH. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 2014;13:529-38. [PMID: 25308364 DOI: 10.1016/s1499-3872(14)60277-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
31 Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Sakoda M, Iino S, Ishigami S, Ueno S, Shinchi H, Natsugoe S. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas. 2013;42:155-159. [PMID: 22699204 DOI: 10.1097/mpa.0b013e318254f2d1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
32 Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Tao H, Chen X, Du Z, Ding K. Corn silk crude polysaccharide exerts anti-pancreatic cancer activity by blocking the EGFR/PI3K/AKT/CREB signaling pathway. Food Funct 2020;11:6961-70. [DOI: 10.1039/d0fo00403k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
34 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
35 Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Koeberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 2011;81:50-4. [PMID: 21921646 DOI: 10.1159/000330769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
36 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810. [PMID: 27160474 DOI: 10.1016/s1470-2045(16)00172-8] [Cited by in Crossref: 416] [Cited by in F6Publishing: 193] [Article Influence: 69.3] [Reference Citation Analysis]
37 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Alvarez-berríos MP, Sosa-cintron N, Rodriguez-lugo M, Juneja R, Vivero-escoto JL. Hybrid Nanomaterials Based on Iron Oxide Nanoparticles and Mesoporous Silica Nanoparticles: Overcoming Challenges in Current Cancer Treatments. Journal of Chemistry 2016;2016:1-15. [DOI: 10.1155/2016/2672740] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
39 Shi K, Damhofer H, Daalhuisen J, Ten Brink M, Richel DJ, Spek CA. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Mol Med 2017;23:13-23. [PMID: 28182192 DOI: 10.2119/molmed.2016.00214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
40 Liu W, Huo Y, Yang J, Fu X, Yang M, Tao L, Liu D, Zhang J, Hua R, Sun Y. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Oncol Lett 2018;15:9287-92. [PMID: 29844826 DOI: 10.3892/ol.2018.8452] [Reference Citation Analysis]
41 Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). J Transl Med 2013;11:311. [PMID: 24330423 DOI: 10.1186/1479-5876-11-311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
42 Matsumoto K, Miyake Y, Kato H, Kawamoto H, Imagawa A, Toyokawa T, Nakatsu M, Ando M, Hirohata M, Yamamoto K. Effect of Low-Dose Gemcitabine on Unresectable Pancreatic Cancer in Elderly Patients. Digestion 2011;84:230-5. [DOI: 10.1159/000330384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
43 Li L, Yue GG, Lau CB, Sun H, Fung KP, Leung PC, Han Q, Leung PS. Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways. Toxicol Appl Pharmacol 2012;262:80-90. [PMID: 22561874 DOI: 10.1016/j.taap.2012.04.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
44 Chen G, Yang G, Long J, Yang J, Qin C, Luo W, Qiu J, Zhao F, You L, Zhang T, Zhao Y. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Front Oncol 2021;11:596573. [PMID: 34123773 DOI: 10.3389/fonc.2021.596573] [Reference Citation Analysis]
45 Sahlström E, Nilsson J, Tingstedt B, Bergenfeldt M, Andersson R, Andersson B. Surgical exploration without resection in pancreatic and periampullary tumors: Report from a national database. Scand J Surg 2021;110:344-50. [DOI: 10.1177/1457496920913669] [Reference Citation Analysis]
46 Kim S, Kang M, Lee S, Bae S, Han S, Jang JY, Park T. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed Eng Online 2014;13 Suppl 2:S5. [PMID: 25560450 DOI: 10.1186/1475-925X-13-S2-S5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
47 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
48 Sakharkar MK, Dhillon SK, Mazumder M, Yang J. Key drug-targeting genes in pancreatic ductal adenocarcinoma. Genes Cancer 2021;12:12-24. [PMID: 33884102 DOI: 10.18632/genesandcancer.210] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Ito Z, Takakura K, Suka M, Kanai T, Saito R, Fujioka S, Kajihara M, Yanagisawa H, Misawa T, Akiba T, Koido S, Ohkusa T. Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. Oncol Lett 2017;13:4799-805. [PMID: 28599481 DOI: 10.3892/ol.2017.6071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Kim YR, Park MK, Kang GJ, Kim HJ, Kim EJ, Byun HJ, Lee M, Lee CH. Leukotriene B4 induces EMT and vimentin expression in PANC-1 pancreatic cancer cells: Involvement of BLT2 via ERK2 activation. Prostaglandins, Leukotrienes and Essential Fatty Acids 2016;115:67-76. [DOI: 10.1016/j.plefa.2016.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
51 Xin Y, Shen XD, Cheng L, Hong DF, Chen B. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Cancer Chemother Pharmacol. 2014;73:711-719. [PMID: 24519751 DOI: 10.1007/s00280-014-2397-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
52 Wu X, Huang J, Yang Z, Zhu Y, Zhang Y, Wang J, Yao W. MicroRNA-221-3p is related to survival and promotes tumour progression in pancreatic cancer: a comprehensive study on functions and clinicopathological value. Cancer Cell Int 2020;20:443. [PMID: 32943991 DOI: 10.1186/s12935-020-01529-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
53 Xu P, Wang X, Qian J, Li Z, Yao J, Xu A. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2021;100:e24651. [PMID: 33578593 DOI: 10.1097/MD.0000000000024651] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Minari JB, Okelola CA, Ugochukwu NC. Analysis of Kras gene from induced pancreatic cancer rats administered with Momordicacharantia and Ocimumbasilicum leaf extracts. J Tradit Complement Med 2018;8:282-8. [PMID: 29736383 DOI: 10.1016/j.jtcme.2017.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 KalantarMotamedi Y, Choi RJ, Koh SB, Bramhall JL, Fan TP, Bender A. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience 2021;24:103080. [PMID: 34585118 DOI: 10.1016/j.isci.2021.103080] [Reference Citation Analysis]
56 Li D, Qian X, Xu P, Wang X, Li Z, Qian J, Yao J. Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing. DNA and Cell Biology 2018;37:839-49. [DOI: 10.1089/dna.2018.4312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
57 Li Y, Xu M. Role of forkhead box M1 in pathogenesis of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(14): 2234-2238 [DOI: 10.11569/wcjd.v23.i14.2234] [Reference Citation Analysis]
58 Tummers WS, Farina-Sarasqueta A, Boonstra MC, Prevoo HA, Sier CF, Mieog JS, Morreau J, van Eijck CH, Kuppen PJ, van de Velde CJ, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:56816-28. [PMID: 28915633 DOI: 10.18632/oncotarget.18232] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
59 Zhang LJ, Wang KB, Liu LS, Chen LZ, Peng BG, Liang LJ, Li Z, Xue L, Li W, Xia JT. Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma. BMC Cancer 2014;14:571. [PMID: 25104140 DOI: 10.1186/1471-2407-14-571] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
60 Sun CY, Zhu HT. Comprehensive surgical management of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2014; 22(2): 159-163 [DOI: 10.11569/wcjd.v22.i2.159] [Reference Citation Analysis]
61 Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Dusetti N, Bartholin L. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. Gut. 2013;Epub ahead of print. [PMID: 24026351 DOI: 10.1136/gutjnl-2013-305221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
62 Lu Y, Hu J, Sun W, Li S, Deng S, Li M. MiR-29c inhibits cell growth, invasion, and migration of pancreatic cancer by targeting ITGB1. Onco Targets Ther 2016;9:99-109. [PMID: 26766915 DOI: 10.2147/OTT.S92758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
63 Pucci MJ, Kennedy EP, Yeo CJ. Pancreatic cancer. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. Elsevier; 2017. pp. 979-987.e2. [DOI: 10.1016/b978-0-323-34062-5.00062-5] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 An N, Cheng D. The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells. Pathol Oncol Res 2020;26:425-31. [PMID: 30406400 DOI: 10.1007/s12253-018-0486-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
65 Lei Y, Hamada Y, Li J, Cong L, Wang N, Li Y, Zheng W, Jiang X. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. J Control Release 2016;232:131-42. [PMID: 27046157 DOI: 10.1016/j.jconrel.2016.03.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
66 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer 2021;21:1319. [PMID: 34886831 DOI: 10.1186/s12885-021-09069-9] [Reference Citation Analysis]
67 Shi J, Guan X, Zhan F, Liu C, Li Z, Yao Y, Wang B, Lou C, Zhang Y. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis. Cancer Biol Ther 2019;20:1290-9. [PMID: 31311398 DOI: 10.1080/15384047.2019.1632143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012;22:106-16. [PMID: 22789542 DOI: 10.1016/j.ccr.2012.05.015] [Cited by in Crossref: 546] [Cited by in F6Publishing: 512] [Article Influence: 54.6] [Reference Citation Analysis]
69 Haeri HH, Tomaszewski J, Phytides B, Schimm H, Möslein G, Niedergethmann M, Hinderberger D, Gelos M. Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. ACS Pharmacol Transl Sci 2020;3:1188-98. [PMID: 33344896 DOI: 10.1021/acsptsci.0c00116] [Reference Citation Analysis]
70 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362-375. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060.computational] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Brychta N, Krahn T, von Ahsen O. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. Clin Chem 2016;62:1482-91. [PMID: 27591291 DOI: 10.1373/clinchem.2016.257469] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
72 Daman Z, Montazeri H, Azizi M, Rezaie F, Ostad SN, Amini M, Gilani K. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer. Pharm Res 2015;32:3756-67. [DOI: 10.1007/s11095-015-1737-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
73 Maier-Stocker C, Bitzer M, Malek NP, Plentz RR. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scand J Gastroenterol 2014;49:1480-5. [PMID: 25390691 DOI: 10.3109/00365521.2014.978816] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Sui X, Sui Z. MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway. Biosci Rep 2020;40:BSR20200010. [PMID: 32484209 DOI: 10.1042/BSR20200010] [Reference Citation Analysis]
75 Malhotra A, Rachet B, Bonaventure A, Pereira SP, Woods LM. Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data. PLoS One 2021;16:e0251876. [PMID: 34077433 DOI: 10.1371/journal.pone.0251876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Horibe Y, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Kozawa O, Shimizu M, Moriwaki H. Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells. Oncol Lett 2016;12:177-82. [PMID: 27347121 DOI: 10.3892/ol.2016.4564] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Liang C, Shi S, Meng Q, Liang D, Hua J, Qin Y, Zhang B, Xu J, Ni Q, Yu X. MiR‐29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. Int J Cancer 2018;143:2919-31. [DOI: 10.1002/ijc.31654] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
78 Xu N, Yang YF, Chen L, Lin J. A Ferritin-Albumin-Cu Nanoparticle that Efficaciously Delivers Copper(II) Ions to a Tumor and Improves the Therapeutic Efficacy of Disulfiram. ACS Omega 2020;5:10415-22. [PMID: 32426598 DOI: 10.1021/acsomega.0c00293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Fokas E, Eccles C, Patel N, Chu KY, Warren S, Gillies McKenna W, Brunner TB. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Strahlenther Onkol 2013;189:407-16. [PMID: 23553047 DOI: 10.1007/s00066-013-0332-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
80 Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B. DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair (Amst) 2021;103:103116. [PMID: 33882393 DOI: 10.1016/j.dnarep.2021.103116] [Reference Citation Analysis]
81 Hung SW, Mody H, Marrache S, Bhutia YD, Davis F, Cho JH, Zastre J, Dhar S, Chu CK, Govindarajan R. Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies. PLoS One 2013;8:e71196. [PMID: 23940717 DOI: 10.1371/journal.pone.0071196] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
82 Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O, Schlitt HJ, Geissler EK, Lang SA. STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia 2012;14:915-25. [PMID: 23097626 DOI: 10.1593/neo.12878] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
83 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
84 Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14:919-929. [PMID: 24833085 DOI: 10.1586/14737140.2014.919860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, Li DM, Zhao Q. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res. 2012;31:29. [PMID: 22458379 DOI: 10.1186/1756-9966-31-29] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
86 Huang S, Chen X, Zheng J, Huang Y, Song L, Yin Y, Xiong J. Low SIRT3 expression contributes to tumor progression, development and poor prognosis in human pancreatic carcinoma. Pathol Res Pract 2017;213:1419-23. [PMID: 28867266 DOI: 10.1016/j.prp.2017.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
87 Li F, Hu G, Jiang Z, Guo J, Wang K, Ouyang K, Wen D, Zhu M, Liang J, Qin X, Zhang L. Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. FEBS J 2012;279:1261-73. [PMID: 22325559 DOI: 10.1111/j.1742-4658.2012.08521.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
88 Köpper F, Binkowski AM, Bierwirth C, Dobbelstein M. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle 2014;13:884-9. [PMID: 24556918 DOI: 10.4161/cc.28292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
89 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
90 Huang S, Zheng J, Huang Y, Song L, Yin Y, Ou D, He S, Chen X, Ouyang X. Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis. Dis Markers. 2016;2016:1-9. [PMID: 26903691 DOI: 10.1155/2016/8137378] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
91 McEwan C, Kamila S, Owen J, Nesbitt H, Callan B, Borden M, Nomikou N, Hamoudi RA, Taylor MA, Stride E, McHale AP, Callan JF. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. Biomaterials 2016;80:20-32. [PMID: 26702983 DOI: 10.1016/j.biomaterials.2015.11.033] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 10.3] [Reference Citation Analysis]
92 Pięt M, Paduch R. Ursolic and Oleanolic Acids as Potential Anticancer Agents Acting in the Gastrointestinal Tract. MROC 2018;16:78-91. [DOI: 10.2174/1570193x15666180612090816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Chen G, Xu L, Ye G, Lin J, Meng Z, Shen Y. Overexpression of a Long Non-Coding RNA BC037916 is Associated with Pancreatic Tumorigenesis and Poor Prognosis. Onco Targets Ther 2020;13:13451-63. [PMID: 33447050 DOI: 10.2147/OTT.S282350] [Reference Citation Analysis]
94 Zhang J, Liu C, Mo X, Shi H, Li S. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer. Oncol Lett 2018;15:1771-6. [PMID: 29434873 DOI: 10.3892/ol.2017.7512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
95 Zeng Z, Xu FY, Zheng H, Cheng P, Chen QY, Ye Z, Zhong JX, Deng SJ, Liu ML, Huang K, Li Q, Li W, Hu YH, Wang F, Wang CY, Zhao G. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics 2019;9:5298-314. [PMID: 31410216 DOI: 10.7150/thno.34559] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
96 Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, Li G, Li H, Chen C, Shi L. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Front Oncol 2021;11:652426. [PMID: 33996572 DOI: 10.3389/fonc.2021.652426] [Reference Citation Analysis]
97 Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, Batra SK. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Semin Immunol 2020;47:101391. [PMID: 31952903 DOI: 10.1016/j.smim.2020.101391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
98 Galván JA, Zlobec I, Wartenberg M, Lugli A, Gloor B, Perren A, Karamitopoulou E. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer 2015;112:1944-50. [PMID: 25989272 DOI: 10.1038/bjc.2015.177] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 14.1] [Reference Citation Analysis]
99 Yoon S, Huang KW, Reebye V, Mintz P, Tien YW, Lai HS, Sætrom P, Reccia I, Swiderski P, Armstrong B, Jozwiak A, Spalding D, Jiao L, Habib N, Rossi JJ. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Mol Ther 2016;24:1106-16. [PMID: 26983359 DOI: 10.1038/mt.2016.60] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
100 Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol 2019;4:28. [PMID: 31231695 DOI: 10.21037/tgh.2019.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
101 Wang H, Cai J, Du S, Wei W, Shen X. LAMC2 modulates the acidity of microenvironments to promote invasion and migration of pancreatic cancer cells via regulating AKT-dependent NHE1 activity. Exp Cell Res 2020;391:111984. [PMID: 32246993 DOI: 10.1016/j.yexcr.2020.111984] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
102 Parajuli P, Singh P, Wang Z, Li L, Eragamreddi S, Ozkan S, Ferrigno O, Prunier C, Razzaque MS, Xu K, Atfi A. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma. EMBO J 2019;38:e101067. [PMID: 31268604 DOI: 10.15252/embj.2018101067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
103 Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010;101:2351-2360. [PMID: 20726858 DOI: 10.1111/j.1349-7006.2010.01671.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
104 Mir-bonafé JM, Román-curto C, Santos-briz Á, Cañueto J, Fernández-lópez E, Unamuno P. Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes. Journal of Cutaneous Pathology 2012;39:707-11. [DOI: 10.1111/j.1600-0560.2012.01918.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
105 Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. PLoS One. 2012;7:e46514. [PMID: 23094026 DOI: 10.1371/journal.pone.0046514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
106 de Wilde RF, Hruban RH, Maitra A, Offerhaus GJA. Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagnostic Histopathology 2012;18:17-30. [DOI: 10.1016/j.mpdhp.2011.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
107 Ferreira CA, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Ni D, Cai W. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Mol Pharm 2020;17:1697-705. [PMID: 32202792 DOI: 10.1021/acs.molpharmaceut.0c00127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
108 Nguyen Kovochich A, Arensman M, Lay AR, Rao NP, Donahue T, Li X, French SW, Dawson DW. HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer 2013;119:529-39. [PMID: 22914903 DOI: 10.1002/cncr.27725] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
109 Braun LM, Lagies S, Klar RFU, Hussung S, Fritsch RM, Kammerer B, Wittel UA. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Cancers (Basel) 2020;12:E1440. [PMID: 32492856 DOI: 10.3390/cancers12061440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
110 Huang H, Zou Y, Zhang H, Li X, Li Y, Deng X, Sun H, Guo Z, Ao L. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Transl Res 2020;219:30-44. [PMID: 32119844 DOI: 10.1016/j.trsl.2020.02.004] [Reference Citation Analysis]
111 Yoo SH, Kang SY, Cheon GJ, Oh DY, Bang YJ. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. J Nucl Med 2020;61:33-9. [PMID: 31201247 DOI: 10.2967/jnumed.119.226407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
112 Yoon S, Rossi JJ. Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA. Adv Exp Med Biol 2017;983:173-88. [PMID: 28639199 DOI: 10.1007/978-981-10-4310-9_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Liu Y, Bi T, Liu L, Gao Q, Shen G, Qin L. RETRACTED ARTICLE: S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn-Schmiedeberg's Arch Pharmacol 2019;392:615-22. [DOI: 10.1007/s00210-019-01617-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
114 Kim D, Lee S, Na K. Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. Small 2021;17:e2006650. [PMID: 33590726 DOI: 10.1002/smll.202006650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014;14:204. [PMID: 24641937 DOI: 10.1186/1471-2407-14-204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
116 Wang J, Wang H, Cai J, Du S, Xin B, Wei W, Zhang T, Shen X. Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-κB signaling. Exp Cell Res 2018;365:12-23. [PMID: 29453972 DOI: 10.1016/j.yexcr.2018.02.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
117 Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: Are there treatment options? World J Gastroenterol 2014; 20(28): 9361-9373 [PMID: 25071331 DOI: 10.3748/wjg.v20.i28.9361] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
118 Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014;3:406-415. [PMID: 24519894 DOI: 10.1002/cam4.204] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
119 Felt SA, Moerdyk-Schauwecker MJ, Grdzelishvili VZ. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology 2015;474:163-73. [PMID: 25463614 DOI: 10.1016/j.virol.2014.10.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
120 Cheng X, Wang B, Jin Z, Ma D, Yang W, Zhao R, Jing X, Shen B, Peng C, Qiu W. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling. Oncotarget 2016;7:77916-25. [PMID: 27788491 DOI: 10.18632/oncotarget.12844] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
121 Krieg A, Riemer JC, Telan LA, Gabbert HE, Knoefel WT. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. PLoS One 2015;10:e0130192. [PMID: 26091099 DOI: 10.1371/journal.pone.0130192] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
122 Huang Y, Zheng J, Tan T, Song L, Huang S, Zhang Y, Lin L, Liu J, Zheng P, Chen X, Chen X, Ouyang X. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. Int J Biol Markers 2018;33:189-94. [PMID: 29076521 DOI: 10.5301/ijbm.5000310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
123 García-García AB, Gómez-Mateo MC, Hilario R, Rentero-Garrido P, Martínez-Domenech A, Gonzalez-Albert V, Cervantes A, Marín-Garcia P, Chaves FJ, Ferrández-Izquierdo A, Sabater L. mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. Oncotarget 2017;8:104796-805. [PMID: 29285214 DOI: 10.18632/oncotarget.20076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 2015;16:43-51. [PMID: 25485960 DOI: 10.4161/15384047.2014.986967] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
125 Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q, Shen G. Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn Schmiedebergs Arch Pharmacol 2015;388:295-304. [PMID: 25418891 DOI: 10.1007/s00210-014-1071-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
126 Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World J Gastroenterol 2014; 20(40): 14717-14725 [PMID: 25356034 DOI: 10.3748/wjg.v20.i40.14717] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
127 Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Cancer Sci 2015;106:1153-62. [PMID: 26132727 DOI: 10.1111/cas.12732] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
128 Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer 2021;21:632. [PMID: 34049503 DOI: 10.1186/s12885-021-08388-1] [Reference Citation Analysis]
129 Martinez-useros J, Li W, Georgiev-hristov T, Fernandez-aceñero MJ, Borrero-palacios A, Perez N, Celdran A, Garcia-foncillas J. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathol Oncol Res 2019;25:269-78. [DOI: 10.1007/s12253-017-0341-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Zhou YJ, Zhu GQ, Zhang QW, Zheng KI, Chen JN, Zhang XT, Wang QW, Li XB. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. DNA Cell Biol 2019;38:1207-22. [PMID: 31483163 DOI: 10.1089/dna.2019.4862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
131 Augustyn A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowski GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee SS, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clin Transl Radiat Oncol 2021;27:147-51. [PMID: 33665384 DOI: 10.1016/j.ctro.2021.02.004] [Reference Citation Analysis]
132 Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Marchesi F. Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Rev Anticancer Ther 2014;14:1219-28. [PMID: 25222571 DOI: 10.1586/14737140.2014.947277] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Du JP, Li L, Zheng J, Zhang D, Liu W, Zheng WH, Li XS, Yao RC, Wang F, Liu S, Tan X. Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer. Oncotarget 2018;9:12894-906. [PMID: 29560118 DOI: 10.18632/oncotarget.24132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
134 Kurahara H, Takao S, Kuwahata T, Nagai T, Ding Q, Maeda K, Shinchi H, Mataki Y, Maemura K, Matsuyama T, Natsugoe S. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol 2012;19:2264-71. [PMID: 22350599 DOI: 10.1245/s10434-012-2263-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
135 Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, Wang Y, Zeng J, Song Y, Gao W. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84. [PMID: 25889214 DOI: 10.1186/s12967-015-0442-z] [Cited by in Crossref: 145] [Cited by in F6Publishing: 153] [Article Influence: 20.7] [Reference Citation Analysis]
136 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
137 Teng Y, Saito E, Abe SK, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Tsugane S. Female reproductive factors, exogenous hormone use, and pancreatic cancer risk: the Japan Public Health Center-based prospective study. European Journal of Cancer Prevention 2017;26:378-84. [DOI: 10.1097/cej.0000000000000358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
138 Attiyeh MA, Amini A, Chung V, Melstrom LG. Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. J Surg Oncol 2021;123:1395-404. [PMID: 33831247 DOI: 10.1002/jso.26415] [Reference Citation Analysis]
139 Ma Y, Yu W, Shrivastava A, Alemi F, Lankachandra K, Srivastava RK, Shankar S. Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway. Carcinogenesis. 2017;38:1047-1056. [PMID: 28968696 DOI: 10.1093/carcin/bgx070] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
140 Rocha-Brito KJP, Fonseca EMB, Oliveira BGF, Fátima Â, Ferreira-Halder CV. Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency. Bioorg Chem 2020;100:103881. [PMID: 32388429 DOI: 10.1016/j.bioorg.2020.103881] [Reference Citation Analysis]
141 Jiang Y, Wang T, Yan L, Qu L. A novel prognostic biomarker for pancreatic ductal adenocarcinoma: hsa_circ_0001649. Gene. 2018;675:88-93. [PMID: 29969694 DOI: 10.1016/j.gene.2018.06.099] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
142 Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
143 Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, Lozano JJ, Bujanda L, Castells A, Gironella M. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia. Clin Transl Gastroenterol 2019;10:e00029. [PMID: 31009404 DOI: 10.14309/ctg.0000000000000029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
144 Gao D, Gao L, Zhang C, Liu H, Jia B, Zhu Z, Wang F, Liu Z. A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer. Biomaterials 2015;53:229-38. [PMID: 25890722 DOI: 10.1016/j.biomaterials.2015.02.093] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
145 Arlt A, Müerköster SS, Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2013;332:346-358. [PMID: 21078544 DOI: 10.1016/j.canlet.2010.10.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
146 Ady JW, Heffner J, Klein E, Fong Y. Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virotherapy. 2014;3:35-46. [PMID: 27512661 DOI: 10.2147/ov.s53858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
147 Hastie E, Besmer DM, Shah NR, Murphy AM, Moerdyk-Schauwecker M, Molestina C, Roy LD, Curry JM, Mukherjee P, Grdzelishvili VZ. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. J Virol 2013;87:10283-94. [PMID: 23864625 DOI: 10.1128/JVI.01412-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
148 Luo K, Li Y, Yin Y, Li L, Wu C, Chen Y, Nowsheen S, Hu Q, Zhang L, Lou Z, Yuan J. USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J 2017;36:1434-46. [PMID: 28363942 DOI: 10.15252/embj.201695669] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
149 Wu X, Cao Y, Xiao H, Li C, Lin J. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther 2016;15:2609-19. [PMID: 27535971 DOI: 10.1158/1535-7163.MCT-15-0921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
150 Loeffler JS, Durante M. Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24. [PMID: 23689752 DOI: 10.1038/nrclinonc.2013.79] [Cited by in Crossref: 259] [Cited by in F6Publishing: 203] [Article Influence: 28.8] [Reference Citation Analysis]
151 Huang C, Du J, Xie K. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochim Biophys Acta 2014;1845:104-16. [PMID: 24418574 DOI: 10.1016/j.bbcan.2014.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
152 Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61:1085-1094. [PMID: 21749982 DOI: 10.1136/gut.2010.236026] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
153 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
154 Xu Y, Liu N, Wei Y, Zhou D, Lin R, Wang X, Shi B. Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells. Aging (Albany NY) 2020;12:19660-76. [PMID: 33040049 DOI: 10.18632/aging.103997] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
155 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
156 Li J, Zhou L, Chen J, Wu B, Zeng J, Fang G, Deng C, Huang S, Yao F, Chen Z, Leng Y, Deng M, Deng C, Zhang B, Zhou G, He L, Liao M, Chiu D, Niu L, Zuo J, Xu K. Pancreatic Head Cryosurgery: Safety and Efficiency In Vivo–A Pilot Study. Pancreas 2012;41:1285-91. [DOI: 10.1097/mpa.0b013e31825544ae] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
157 Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surg Clin North Am 2016;96:1415-30. [PMID: 27865285 DOI: 10.1016/j.suc.2016.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
158 Luo M, Chen J, Zhong Z, Zhang F. CT-guided 125I brachytherapy combined with chemotherapy for the treatment of unresectable or locally advanced pancreatic carcinoma. Diagn Interv Radiol 2021;27:50-8. [PMID: 33252336 DOI: 10.5152/dir.2020.19371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer 2011;104:1882-9. [PMID: 21587259 DOI: 10.1038/bjc.2011.166] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
160 Hwang JW, Jang SK, Lee DJ. Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes. Medicine (Baltimore) 2021;100:e24969. [PMID: 33832071 DOI: 10.1097/MD.0000000000024969] [Reference Citation Analysis]
161 Shi M, Xie D, Gaod Y, Xie K. Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des 2014;20:5279-86. [PMID: 24479803 DOI: 10.2174/1381612820666140128210443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
162 Lee J, Hun Yun J, Lee J, Choi C, Hoon Kim J. Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells. Sci Rep 2015;5:12296. [PMID: 26212664 DOI: 10.1038/srep12296] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
163 Zhong Y, Naito Y, Cope L, Naranjo-Suarez S, Saunders T, Hong SM, Goggins MG, Herman JM, Wolfgang CL, Iacobuzio-Donahue CA. Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. Clin Cancer Res. 2014;20:6200-6211. [PMID: 24963048 DOI: 10.1158/1078-0432.ccr-13-2823] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
164 Yao M, Hong Y, Liu Y, Chen W, Wang W. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2. Exp Ther Med. 2017;14:2101-2107. [PMID: 28962130 DOI: 10.3892/etm.2017.4740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
165 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
166 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
167 Yoon S, Rossi JJ. Emerging cancer-specific therapeutic aptamers. Curr Opin Oncol 2017;29:366-74. [PMID: 28692589 DOI: 10.1097/CCO.0000000000000389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
168 Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S, Xie K. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012;72:655-665. [PMID: 22194465 DOI: 10.1158/0008-5472.CAN-11-3102] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
169 Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 2016;119:306-11. [PMID: 27117177 DOI: 10.1016/j.radonc.2016.03.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
170 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
171 Xia X, Zhang K, Cen G, Jiang T, Cao J, Huang K, Huang C, Zhao Q, Qiu Z. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Oncotarget. 2015;6:21046-21063. [PMID: 26019136 DOI: 10.18632/oncotarget.4124] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
172 Sun Z, Sun D, Feng Y, Zhang B, Sun P, Zhou B, Du L, Wang Y, Fan Z, Yang J, Li Y, Hu S, Zhan H. Exosomal linc-ROR mediates crosstalk between cancer cells and adipocytes to promote tumor growth in pancreatic cancer. Mol Ther Nucleic Acids 2021;26:253-68. [PMID: 34513308 DOI: 10.1016/j.omtn.2021.06.001] [Reference Citation Analysis]
173 Charalambous P, Moris D, Karachaliou GS, Papalampros A, Dimitrokallis N, Tsilimigras DI, Oikonomou D, Petrou A. The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. Eur J Surg Oncol 2020;46:1565-72. [PMID: 32536525 DOI: 10.1016/j.ejso.2020.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
174 Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH. Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. J Cell Biochem 2010;111:1160-8. [PMID: 20717927 DOI: 10.1002/jcb.22828] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
175 Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemother Pharmacol 2015;75:683-90. [PMID: 25618415 DOI: 10.1007/s00280-015-2683-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
176 Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua CY, Phillips LM, Ren H, Fleming JB, Wang H, Chiao PJ, Hao J, Zhang W. IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Cancer Res 2016;76:6543-54. [PMID: 27659045 DOI: 10.1158/0008-5472.CAN-16-0438] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
177 Wu P, Wang X, Ma Y, Xu X, Liu W, Sheng Z, Chen M, Zhou R, Zhang K, Goodin S, Zheng X, Li D. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorg Chem 2020;101:104022. [PMID: 32599367 DOI: 10.1016/j.bioorg.2020.104022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Liu J, Xie X, Xuan C, Li T, Wang L, Teng L, Liu J. High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer. Pancreas 2018;47:725-31. [PMID: 29771768 DOI: 10.1097/MPA.0000000000001059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
179 Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, Elferink LA. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One 2012;7:e40420. [PMID: 22815748 DOI: 10.1371/journal.pone.0040420] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
180 Chen JB, Li JL, He LH, Liu WQ, Yao F, Zeng JY, Zhang Y, Xu KQ, Niu LZ, Zuo JS, Xu KC. Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol 2012; 18(47): 7056-7062 [PMID: 23323008 DOI: 10.3748/wjg.v18.i47.7056] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
181 Gooden HM, White KJ. Pancreatic cancer and supportive care--pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer. 2013;21:1835-1841. [PMID: 23397095 DOI: 10.1007/s00520-013-1729-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
182 Zhang Z, Qin W, Sun Y. Contribution of biomarkers for pancreatic cancer-associated new-onset diabetes to pancreatic cancer screening. Pathol Res Pract 2018;214:1923-8. [PMID: 30477640 DOI: 10.1016/j.prp.2018.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
183 Tang B, Li Y, Qi G, Yuan S, Wang Z, Yu S, Li B, He S. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer. Sci Rep 2015;5:13563. [PMID: 26338139 DOI: 10.1038/srep13563] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
184 Huang S, Zhang X, Luo K, Jiang L, Jiang J, Li R. Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition. Front Oncol 2022;11:762233. [DOI: 10.3389/fonc.2021.762233] [Reference Citation Analysis]
185 Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer 2016;16:632. [PMID: 27520560 DOI: 10.1186/s12885-016-2540-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
186 Fokas E, Eccles C, Patel N, Chu K, Warren S, Mckenna WG, Brunner TB. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiotherapy and Oncology 2013;107:200-6. [DOI: 10.1016/j.radonc.2013.04.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
187 Jiang W, Bai W, Li J, Liu J, Zhao K, Ren L. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer. Int J Cancer 2021;148:1006-13. [PMID: 32914874 DOI: 10.1002/ijc.33291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Aravindan S, Ramraj S, Kandasamy K, Thirugnanasambandan SS, Somasundaram DB, Herman TS, Aravindan N. Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells. Oncotarget 2017;8:5717-34. [PMID: 27974694 DOI: 10.18632/oncotarget.13900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
189 Nitipir C, Vrabie R, Parosanu AI, Tulin R, Cretu B, Cursaru A, Slavu I, Miron A, Calu V, Orlov Slavu MC. Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study. Cureus 2021;13:e19361. [PMID: 34925974 DOI: 10.7759/cureus.19361] [Reference Citation Analysis]
190 Zhang JH, Lai FJ, Chen H, Luo J, Zhang RY, Bu HQ, Wang ZH, Lin HH, Lin SZ. Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1. Oncol Lett 2013;5:43-8. [PMID: 23255891 DOI: 10.3892/ol.2012.991] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
191 Zheng S, Chen H, Wang Y, Gao W, Fu Z, Zhou Q, Jiang Y, Lin Q, Tan L, Ye H, Zhao X, Luo Y, Li G, Ye L, Liu Y, Li W, Li Z, Chen R. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner. Cancer Lett 2016;371:354-65. [PMID: 26708505 DOI: 10.1016/j.canlet.2015.12.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
192 Lee J, Lee JC, Gromski MA, Kim HW, Kim J, Kim J, Hwang JH. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Medicine (Baltimore) 2018;97:e13592. [PMID: 30558029 DOI: 10.1097/MD.0000000000013592] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
193 Zhou Y, Zhou Y, Yang M, Wang K, Liu Y, Zhang M, Yang Y, Jin C, Wang R, Hu R. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol 2019;22:101131. [PMID: 30735911 DOI: 10.1016/j.redox.2019.101131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
194 Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA. Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. Cancer Growth Metastasis 2015;8:95-113. [PMID: 26512205 DOI: 10.4137/CGM.S29407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
195 Hertzer KM, Donald GW, Hines OJ. CXCR2: a target for pancreatic cancer treatment? Expert Opin Ther Targets 2013;17:667-80. [PMID: 23425074 DOI: 10.1517/14728222.2013.772137] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
196 Soweid AM. The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition. Endosc Ultrasound 2017;6:S76-8. [PMID: 29387696 DOI: 10.4103/eus.eus_66_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
197 Freeman K, Connock M, Cummins E, Gurung T, Taylor-Phillips S, Court R, Saunders M, Clarke A, Sutcliffe P. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess 2015;19:1-321, v-vi. [PMID: 26542268 DOI: 10.3310/hta19910] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
198 Shi LE, Shang X, Nie KC, Xu Q, Chen NB, Zhu ZZ. Identification of potential crucial genes associated with the pathogenesis and prognosis of pancreatic adenocarcinoma. Oncol Lett 2020;20:60. [PMID: 32793313 DOI: 10.3892/ol.2020.11921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther. 2015;9:1247-1255. [PMID: 25750521 DOI: 10.2147/dddt.s77597] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
200 Zhang KJ, Dyson G, Gatz JL, Silverman ME, Tesfaye AA, Shields AF, Philip PA. Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center. Am J Clin Oncol 2019;42:243-6. [PMID: 30601178 DOI: 10.1097/COC.0000000000000507] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
201 Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55-68. [PMID: 26690340 DOI: 10.1016/j.drup.2015.10.002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 128] [Article Influence: 16.9] [Reference Citation Analysis]
202 Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci 2012;8:1-14. [PMID: 22211100 DOI: 10.7150/ijbs.8.1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
203 Long H, Li Q, Wang Y, Li Q, Liu T, Peng J. Effective combination gene therapy using CEACAM6-shRNA and the fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro. Exp Ther Med 2013;5:155-61. [PMID: 23251258 DOI: 10.3892/etm.2012.774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
204 He TL, Zhang YJ, Jiang H, Li XH, Zhu H, Zheng KL. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med Oncol. 2015;32:187. [PMID: 26021472 DOI: 10.1007/s12032-015-0633-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
205 Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014;8:739-747. [PMID: 24882381 DOI: 10.1586/17474124.2014.925799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
206 Yousuf I, Usman M, Ahmad M, Tabassum S, Arjmand F. Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag( i ) nalidixic acid–piperazinium drug entity specific for pancreatic cancer cells. New J Chem 2018;42:506-19. [DOI: 10.1039/c7nj03602g] [Cited by in Crossref: 13] [Article Influence: 3.3] [Reference Citation Analysis]
207 Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676-1681. [PMID: 21565490 DOI: 10.1016/j.ejca.2011.04.011] [Cited by in Crossref: 214] [Cited by in F6Publishing: 188] [Article Influence: 19.5] [Reference Citation Analysis]
208 Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2014;40:109-117. [PMID: 23583268 DOI: 10.1016/j.ctrv.2013.03.002] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 12.8] [Reference Citation Analysis]
209 Li Y, Dong M, Sheng W, Huang L. Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer. Pathol Oncol Res 2016;22:277-86. [PMID: 26224207 DOI: 10.1007/s12253-015-9935-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
210 Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. [PMID: 29875415 DOI: 10.1038/s41598-018-26811-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
211 Parker LA, Porta M, Lumbreras B, López T, Guarner L, Hernández-Aguado I, Carrato A, Corominas JM, Rifà J, Fernandez E, Alguacil J, Malats N, Real FX. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol 2011;26:229-36. [PMID: 21298467 DOI: 10.1007/s10654-011-9547-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
212 Li X, Xu JX. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy. J Theor Biol 2016;406:42-51. [PMID: 27338302 DOI: 10.1016/j.jtbi.2016.06.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
213 Jaidev LR, Chellappan DR, Bhavsar DV, Ranganathan R, Sivanantham B, Subramanian A, Sharma U, Jagannathan NR, Krishnan UM, Sethuraman S. Multi-functional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer. Acta Biomater 2017;49:422-33. [PMID: 27890622 DOI: 10.1016/j.actbio.2016.11.053] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
214 Sumiyoshi H, Matsushita A, Nakamura Y, Matsuda Y, Ishiwata T, Naito Z, Uchida E. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Oncol Rep 2016;35:3216-26. [PMID: 27035235 DOI: 10.3892/or.2016.4727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
215 Moysan E, Bastiat G, Benoit JP. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm. 2013;10:430-444. [PMID: 22978251 DOI: 10.1021/mp300370t] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 12.3] [Reference Citation Analysis]
216 Chen SJ, Zhang QB, Zeng LJ, Lian GD, Li JJ, Qian CC, Chen YZ, Chen YT, Huang KH. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Curr Oncol. 2015;22:e11-e19. [PMID: 25684992 DOI: 10.3747/co.22.2150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
217 Hagoel L, Vexler A, Kalich-Philosoph L, Earon G, Ron I, Shtabsky A, Marmor S, Lev-Ari S. Combined Effect of Moringa oleifera and Ionizing Radiation on Survival and Metastatic Activity of Pancreatic Cancer Cells. Integr Cancer Ther 2019;18:1534735419828829. [PMID: 30862207 DOI: 10.1177/1534735419828829] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
218 Wei X, Yang J, Mao Y, Zhao H, Si N, Wang H, Bian B. Arenobufagin Inhibits the Phosphatidylinositol 3-kinase/Protein Kinase B/Mammalian Target of Rapamycin Pathway and Induces Apoptosis and Autophagy in Pancreatic Cancer Cells. Pancreas 2020;49:261-72. [DOI: 10.1097/mpa.0000000000001471] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Koido S, Okamoto M, Shimodaira S, Sugiyama H. Wilms’ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy 2016;8:1309-20. [DOI: 10.2217/imt-2016-0031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
220 Yuan YH, Zhou J, Zhang Y, Xu MD, Wu J, Li W, Wu MY, Li DM. Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis. Oncol Lett 2019;18:1117-32. [PMID: 31423172 DOI: 10.3892/ol.2019.10444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
221 Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, Chen H, Zhang J, Li Q. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori 2016;2016:294-300. [PMID: 27056335 DOI: 10.5301/tj.5000499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
222 Li J, Liu F, Gupta S, Li C. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma. Theranostics. 2016;6:1393-1402. [PMID: 27375787 DOI: 10.7150/thno.15122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
223 Chu W, Tian P, Ding N, Cai Q, Li J, Zhuo X, Tang Z, Gou J, Yin T, Zhang Y, He H, Tang X. Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2506-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
224 Attard CL, Brown S, Alloul K, Moore MJ. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol. 2014;21:e41-e51. [PMID: 24523620 DOI: 10.3747/co.21.1327] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
225 Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N, Yu J, Lee S, Kim J, Qin B, Xie F, Evans D, Wang L, Lou W, Lou Z. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 2016;76:572-81. [PMID: 26676747 DOI: 10.1158/0008-5472.CAN-15-0671] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
226 He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh) 2018;5:1701070. [PMID: 29876225 DOI: 10.1002/advs.201701070] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
227 Pang E, Yang R, Fu X, Liu Y. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol 2015;36:2403-7. [DOI: 10.1007/s13277-014-2850-8] [Cited by in Crossref: 119] [Cited by in F6Publishing: 130] [Article Influence: 14.9] [Reference Citation Analysis]
228 Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-503. [PMID: 21460848 DOI: 10.1038/nm.2344.subtypes] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol. 2012;2:209. [PMID: 23316479 DOI: 10.3389/fonc.2012.00209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
230 Jenkinson C, Earl J, Ghaneh P, Halloran C, Carrato A, Greenhalf W, Neoptolemos J, Costello E. Biomarkers for early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2015;9:305-315. [PMID: 25373768 DOI: 10.1586/17474124.2015.965145] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
231 Bi Y, Min M, Shen W, Liu Y. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity. Tumor Biol 2016;37:15145-55. [DOI: 10.1007/s13277-016-5311-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
232 Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10:37. [PMID: 21489257 DOI: 10.1186/1476-4598-10-37] [Cited by in Crossref: 135] [Cited by in F6Publishing: 142] [Article Influence: 12.3] [Reference Citation Analysis]
233 Huang C, Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 2012;23:25-35. [PMID: 22342309 DOI: 10.1016/j.cytogfr.2012.01.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
234 Sherman S, Shats O, Ketcham MA, Anderson MA, Whitcomb DC, Lynch HT, Ghiorzo P, Rubinstein WS, Sasson AR, Grizzle WE, Haynatzki G, Feng J, Sherman A, Kinarsky L, Brand RE. PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 2011;10:83-91. [PMID: 21552494 DOI: 10.4137/CIN.S6919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
235 Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF, Kocher HM, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR, Chelala C. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med 2014;6:105. [PMID: 25587357 DOI: 10.1186/s13073-014-0105-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
236 Greer JB, Brand RE. New developments in pancreatic cancer. Curr Gastroenterol Rep. 2011;13:131-139. [PMID: 21258973 DOI: 10.1007/s11894-011-0175-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
237 Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Exp Mol Pathol. 2015;98:1-6. [PMID: 25445504 DOI: 10.1016/j.yexmp.2014.11.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
238 Wang L, Barth CW, Sibrian-Vazquez M, Escobedo JO, Lowry M, Muschler J, Li H, Gibbs SL, Strongin RM. Far-Red and Near-Infrared Seminaphthofluorophores for Targeted Pancreatic Cancer Imaging. ACS Omega 2017;2:154-63. [PMID: 28180189 DOI: 10.1021/acsomega.6b00403] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
239 Huang S, Guo H, Cao Y, Xiong J. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. Pathol Res Pract 2019;215:794-800. [PMID: 30683474 DOI: 10.1016/j.prp.2019.01.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
240 Saccomandi P, Larocca ES, Rendina V, Schena E, D'Ambrosio R, Crescenzi A, Di Matteo FM, Silvestri S. Estimation of optical properties of neuroendocrine pancreas tumor with double-integrating-sphere system and inverse Monte Carlo model. Lasers Med Sci 2016;31:1041-50. [PMID: 27147075 DOI: 10.1007/s10103-016-1948-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
241 Vuijk FA, de Muynck LDAN, Franken LC, Busch OR, Wilmink JW, Besselink MG, Bonsing BA, Bhairosingh SS, Kuppen PJK, Mieog JSD, Sier CFM, Vahrmeijer AL, Verheij J, Fariňa-Sarasqueta A, Swijnenburg RJ. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci Rep 2020;10:16211. [PMID: 33004930 DOI: 10.1038/s41598-020-73242-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Mu GG, Zhang LL, Li HY, Liao Y, Yu HG. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. Dig Dis Sci. 2015;60:1067-1080. [PMID: 25344906 DOI: 10.1007/s10620-014-3394-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
243 Zhang WY, Jin ZD, Liu F, Yuan HH, Jiang B. Antitumor Activity of Intratumoral Ethanol Injection in an Orthotopic Pancreatic Cancer Cell Mouse Xenograft Model. Gastroenterol Res Pract 2018;2018:7149565. [PMID: 29675041 DOI: 10.1155/2018/7149565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 Xu J, Yuan S, Tian J, Martin KA, Song J, Li C, Wang Z, Lin J, Si T, Xu RX. Ultrasound mediated delivery of oxygen and LLL12 loaded stimuli responsive microdroplets for the treatment of hypoxic cancer cells. Sci Rep 2017;7:44908. [PMID: 28322306 DOI: 10.1038/srep44908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
245 Xu HN, Nioka S, Li LZ. Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model. Biomark Res 2013;1:6. [PMID: 24252270 DOI: 10.1186/2050-7771-1-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
246 Liu C, Wang H, Li H, Chen X, Wu X, Lu B, Zhang W, Zhou Y, Xiao GG, Gao G. Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway–Meditated Epithelial-Mesenchymal Transition. Pancreas 2019;48:629-35. [DOI: 10.1097/mpa.0000000000001321] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
247 Chen H, Lu W, Huang C, Ding K, Xia D, Wu Y, Cai M. Prognostic significance of ZEB1 and ZEB2 in digestive cancers: a cohort-based analysis and secondary analysis. Oncotarget 2017;8:31435-48. [PMID: 28416756 DOI: 10.18632/oncotarget.15634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
248 Chen G, Xu YP, Sun CH, Qiu YK. Clinical efficacy of gemcitabine combined with intensity modulated radiotherapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2017; 25(16): 1511-1515 [DOI: 10.11569/wcjd.v25.i16.1511] [Reference Citation Analysis]
249 Nahire R, Hossain R, Patel R, Paul S, Meghnani V, Ambre AH, Gange KN, Katti KS, Leclerc E, Srivastava DK, Sarkar K, Mallik S. pH-triggered echogenicity and contents release from liposomes. Mol Pharm 2014;11:4059-68. [PMID: 25271780 DOI: 10.1021/mp500186a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
250 Grupp K, Melling N, Bogoevska V, Reeh M, Uzunoglu FG, El Gammal AT, Nentwich MF, Izbicki JR, Bogoevski D. Expression of ICAM-1, E-cadherin, periostin and midkine in metastases of pancreatic ductal adenocarcinomas. Exp Mol Pathol. 2018;104:109-113. [PMID: 29355490 DOI: 10.1016/j.yexmp.2018.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
251 He XY, Yuan YZ. Advances in pancreatic cancer research: Moving towards early detection. World J Gastroenterol 2014; 20(32): 11241-11248 [PMID: 25170208 DOI: 10.3748/wjg.v20.i32.11241] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
252 Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, Li Y, Tang Y. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett 2015;356:613-27. [PMID: 25305448 DOI: 10.1016/j.canlet.2014.10.008] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 9.9] [Reference Citation Analysis]
253 El-heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges TM, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P. In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. Clinical Chemistry 2018;64:536-46. [DOI: 10.1373/clinchem.2017.281295] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 12.5] [Reference Citation Analysis]
254 Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 2016;142:1137-61. [PMID: 26250876 DOI: 10.1007/s00432-015-2024-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
255 Kim JH, Kim H, Kim YJ, Lee JY, Han JK, Choi BI. Dynamic contrast-enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer. Eur Radiol 2014;24:2059-68. [PMID: 24962825 DOI: 10.1007/s00330-014-3260-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
256 Park JK, Paik WH, Song BJ, Ryu JK, Kim MA, Park JM, Lee SH, Kim YT. Additional K-ras mutation analysis and Plectin-1 staining improve the diagnostic accuracy of pancreatic solid mass in EUS-guided fine needle aspiration. Oncotarget 2017;8:64440-8. [PMID: 28969083 DOI: 10.18632/oncotarget.16135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
257 Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J, Zhu Z, Gao Y, Xie K. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. 2014;20:4370-4380. [PMID: 24947925 DOI: 10.1158/1078-0432.ccr-14-0186] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
258 Qiu B, Zhang X, Tsauo J, Zhao H, Gong T, Li J, Li X. Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review. Abdom Radiol (NY) 2019;44:2801-8. [PMID: 31025067 DOI: 10.1007/s00261-019-02022-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
259 Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, Eckhardt SG, Messersmith WA, Pitts TM. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:642328. [PMID: 33869031 DOI: 10.3389/fonc.2021.642328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
260 Chen B, Xu M, Zhang H, Xu MZ, Wang XJ, Tang QH, Tang JY. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. DNA Cell Biol 2015;34:610-7. [PMID: 26284306 DOI: 10.1089/dna.2015.2886] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
261 Chen SH, Li DL, Yang F, Wu Z, Zhao YY, Jiang Y. Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation. Biochimie. 2014;103:71-79. [PMID: 24732633 DOI: 10.1016/j.biochi.2014.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
262 Ma B, Ran R, Liao HY, Zhang HH. The paradoxical role of matrix metalloproteinase-11 in cancer. Biomed Pharmacother 2021;141:111899. [PMID: 34346316 DOI: 10.1016/j.biopha.2021.111899] [Reference Citation Analysis]
263 Liu Z, Li D, Zhao W, Zheng X, Wang J, Wang E. A potent lead induces apoptosis in pancreatic cancer cells. PLoS One 2012;7:e37841. [PMID: 22745658 DOI: 10.1371/journal.pone.0037841] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
264 Williamson EA, Boyle TJ, Raymond R, Farrington J, Verschraegen C, Shaheen M, Hromas R. Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells. Invest New Drugs 2012;30:114-20. [PMID: 20820908 DOI: 10.1007/s10637-010-9530-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
265 Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res. 2013;73:3987-3996. [PMID: 23598278 DOI: 10.1158/0008-5472.CAN-12-3859] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
266 Alasadi A, Cao B, Guo J, Tao H, Collantes J, Tan V, Su X, Augeri D, Jin S. Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models. Oncogene 2021;40:2285-95. [PMID: 33649533 DOI: 10.1038/s41388-021-01688-7] [Reference Citation Analysis]
267 He C, Wang J, Zhang Y, Cai Z, Lin X, Li S. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. Cancer Med. 2020;9:4699-4710. [PMID: 32410380 DOI: 10.1002/cam4.3119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
268 Li H, Wang P, Deng Y, Zeng M, Tang Y, Zhu W, Cheng Y. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma. Biomaterials 2017;139:30-8. [DOI: 10.1016/j.biomaterials.2017.05.030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
269 Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Seminars in Immunology 2014;26:80-7. [DOI: 10.1016/j.smim.2014.01.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
270 Zhu W, Li J, Wu S, Li S, Le L, Su X, Qiu P, Hu H, Yan G. Triptolide cooperates with Cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas. 2012;41:1029-1038. [PMID: 22617708 DOI: 10.1097/mpa.0b013e31824abdc0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
271 Zeleniak AE, Huang W, Brinkman MK, Fishel ML, Hill R. Loss of MTSS1 results in increased metastatic potential in pancreatic cancer. Oncotarget 2017;8:16473-87. [PMID: 28146435 DOI: 10.18632/oncotarget.14869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
272 Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13:1072-1081. [PMID: 22825331 DOI: 10.4161/cbt.21093] [Cited by in Crossref: 166] [Cited by in F6Publishing: 147] [Article Influence: 16.6] [Reference Citation Analysis]
273 Li W, Zhu Y, Zhang K, Yu X, Lin H, Wu W, Peng Y, Sun J. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. Exp Mol Med 2020;52:409-22. [PMID: 32123287 DOI: 10.1038/s12276-020-0390-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
274 Johnson J, de Mejia EG. Dietary factors and pancreatic cancer: the role of food bioactive compounds. Mol Nutr Food Res 2011;55:58-73. [PMID: 21207513 DOI: 10.1002/mnfr.201000420] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
275 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology 2016;16:1051-6. [DOI: 10.1016/j.pan.2016.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
276 Maginn EN, de Sousa CH, Wasan HS, Stronach EA. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Biochim Biophys Acta 2014;1846:45-54. [PMID: 24727386 DOI: 10.1016/j.bbcan.2014.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
277 Zhao W, Li D, Liu Z, Zheng X, Wang J, Wang E. Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells. PLoS One 2013;8:e66362. [PMID: 23840452 DOI: 10.1371/journal.pone.0066362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
278 Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Comparative Outcomes Between Initially Unresectable and Recurrent Cases of Advanced Pancreatic Cancer Following Palliative Chemotherapy. Pancreas 2014;43:411-6. [DOI: 10.1097/mpa.0000000000000050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
279 Wang S, Huang S, Sun YL. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int. 2017;2017:2646148. [PMID: 29379795 DOI: 10.1155/2017/2646148] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
280 Luan YP, Li QF, Wu SG, Mao DC, Deng YY, Chen RW. Tsoong induces apoptosis and inhibits proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Med Rep 2018;17:3527-36. [PMID: 29286105 DOI: 10.3892/mmr.2017.8328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
281 Jiang SH, Wang Y, Yang JY, Li J, Feng MX, Wang YH, Yang XM, He P, Tian GA, Zhang XX, Li Q, Cao XY, Huo YM, Yang MW, Fu XL, Li J, Liu DJ, Dai M, Wen SY, Gu JR, Hong J, Hua R, Zhang ZG, Sun YW. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Oncotarget 2016;7:4226-40. [PMID: 26735172 DOI: 10.18632/oncotarget.6772] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
282 Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol 2015; 7(10): 241-249 [PMID: 26483878 DOI: 10.4251/wjgo.v7.i10.241] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
283 Antwi SO, Eckert EC, Sabaque CV, Leof ER, Hawthorne KM, Bamlet WR, Chaffee KG, Oberg AL, Petersen GM. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control 2015;26:1583-91. [PMID: 26293241 DOI: 10.1007/s10552-015-0652-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
284 Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget 2017;8:19760-7. [PMID: 28178665 DOI: 10.18632/oncotarget.15035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
285 Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Cancer Res 2018;78:3783-92. [PMID: 29792309 DOI: 10.1158/0008-5472.CAN-18-0491] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
286 Guo N, Liu Z, Zhao W, Wang E, Wang J. Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling. PLoS One 2016;11:e0155874. [PMID: 27223122 DOI: 10.1371/journal.pone.0155874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
287 Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S, Gao Y, Huang S, Xie K. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014;20:2595-2606. [PMID: 24634381 DOI: 10.1158/1078-0432.ccr-13-2407] [Cited by in Crossref: 118] [Cited by in F6Publishing: 88] [Article Influence: 14.8] [Reference Citation Analysis]
288 Palzer J, Eckstein L, Slabu I, Reisen O, Neumann UP, Roeth AA. Iron Oxide Nanoparticle-Based Hyperthermia as a Treatment Option in Various Gastrointestinal Malignancies. Nanomaterials (Basel) 2021;11:3013. [PMID: 34835777 DOI: 10.3390/nano11113013] [Reference Citation Analysis]
289 Borgoni S, Iannello A, Cutrupi S, Allavena P, D'Incalci M, Novelli F, Cappello P. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncoimmunology 2018;7:e1393596. [PMID: 29308326 DOI: 10.1080/2162402X.2017.1393596] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
290 Liu YA, Zhang Y, Zheng Z, Li K, Wu XH, Du QG, Ye X, Wang L, Zhu L. MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protein kinase 1. Oncol Lett 2018;15:6745-51. [PMID: 29616134 DOI: 10.3892/ol.2018.8109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
291 Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ; Australian Pancreatic Cancer Genome Initiative, Chang DK, Biankin AV, Waddell N, Kassahn KS, Grimmond SM, Rust AG, Adams DJ, Jenkins NA, Copeland NG. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2012;109:5934-5941. [PMID: 22421440 DOI: 10.1073/pnas.1202490109] [Cited by in Crossref: 164] [Cited by in F6Publishing: 151] [Article Influence: 16.4] [Reference Citation Analysis]
292 Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 2012;86:3073-87. [PMID: 22238308 DOI: 10.1128/JVI.05640-11] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
293 Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, Nonaka T, Ishikawa H, Okumura T, Sakurai H. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol 2019;136:37-43. [PMID: 31015127 DOI: 10.1016/j.radonc.2019.03.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
294 Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, Dimas K, Kusano T, Shively J, Habib N, Rossi JJ. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Mol Ther Nucleic Acids 2017;6:80-8. [PMID: 28325302 DOI: 10.1016/j.omtn.2016.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
295 Foulkes R, Ali Asgari M, Curtis A, Hoskins C. Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer. ACS Appl Nano Mater 2019;2:1758-72. [DOI: 10.1021/acsanm.9b00439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
296 Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, Sipos B, Malek NP, Plentz RR. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogenesis 2014;35:859-66. [DOI: 10.1093/carcin/bgt394] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
297 Ahn K, O YM, Ji YG, Cho HJ, Lee DH. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells. Yonsei Med J 2018;59:727-35. [PMID: 29978609 DOI: 10.3349/ymj.2018.59.6.727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Goto S, Seino H, Yoshizawa T, Morohashi S, Ishido K, Hakamada K, Kijima H. Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. Oncol Lett 2021;21:276. [PMID: 33732352 DOI: 10.3892/ol.2021.12537] [Reference Citation Analysis]
299 Liu C, Shi J, Li Q, Li Z, Lou C, Zhao Q, Zhu Y, Zhan F, Lian J, Wang B, Guan X, Fang L, Li Z, Wang Y, Zhou B, Yao Y, Zhang Y. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Clin Sci (Lond) 2019;133:645-63. [PMID: 30782607 DOI: 10.1042/CS20180816] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
300 Li J, Li H, Zhu W, Zhou B, Ying J, Wu J, Zhang H, Sun H, Gao S. Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma. J Cell Mol Med 2020;24:1370-82. [PMID: 31845546 DOI: 10.1111/jcmm.14813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
301 Adams MS, Scott SJ, Salgaonkar VA, Sommer G, Diederich CJ. Thermal therapy of pancreatic tumours using endoluminal ultrasound: Parametric and patient-specific modelling. Int J Hyperthermia 2016;32:97-111. [PMID: 27097663 DOI: 10.3109/02656736.2015.1119892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
302 Shah N, Zhai G, Knowles JA, Stockard CR, Grizzle WE, Fineberg N, Zhou T, Zinn KR, Rosenthal EL, Kim H. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 2012;14:237-44. [PMID: 21494920 DOI: 10.1007/s11307-011-0491-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
303 Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012;18:2439-51. [PMID: 22372502 DOI: 10.2174/13816128112092439] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
304 May V, Berchtold S, Berger A, Venturelli S, Burkard M, Leischner C, Malek NP, Lauer UM. Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus. Oncol Lett 2019;18:5534-42. [PMID: 31612061 DOI: 10.3892/ol.2019.10901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
305 Smith JK, Chu QD, Tseng JF. Pancreatic Adenocarcinoma. In: Chu QD, Gibbs JF, Zibari GB, editors. Surgical Oncology. New York: Springer; 2015. pp. 283-313. [DOI: 10.1007/978-1-4939-1423-4_13] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
306 Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer 2013;108:1846-53. [PMID: 23579209 DOI: 10.1038/bjc.2013.150] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
307 Yang F, Jin C, Jiang Y, Li J, Di Y, Ni Q, Fu D. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev. 2011;37:633-642. [PMID: 21330062 DOI: 10.1016/j.ctrv.2011.01.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
308 Chang ZG, Wei JM, Qin CF, Hao K, Tian XD, Xie K, Xie XH, Yang YM. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Dig Dis Sci. 2012;57:1181-1189. [PMID: 22271412 DOI: 10.1007/s10620-012-2036-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
309 Yang J, Jiang Y, He R, Liu W, Yang M, Tao L, Fu X, Shen Y, Li J, Liu D, Huo Y, Zhang J, Hua R, Zhang Z, Sun Y. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. J Immunol Res 2019;2019:8656282. [PMID: 31583260 DOI: 10.1155/2019/8656282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
310 Suvarna V, Murahari M, Khan T, Chaubey P, Sangave P. Phytochemicals and PI3K Inhibitors in Cancer-An Insight. Front Pharmacol 2017;8:916. [PMID: 29311925 DOI: 10.3389/fphar.2017.00916] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
311 Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37:105-114. [PMID: 24509173 DOI: 10.1097/cji.0000000000000020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
312 Wang X, Dou N, Wang J, Zhang Y, Li Y, Gao Y. FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes. Int J Biol Sci 2021;17:915-25. [PMID: 33867818 DOI: 10.7150/ijbs.56733] [Reference Citation Analysis]
313 Lee J, Han S, Yun J, Kim JH. Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells. Tumor Biol 2015;36:9385-93. [DOI: 10.1007/s13277-015-3682-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
314 Arvaniti M, Danias N, Igoumenidis M, Smyrniotis V, Tsounis A, Sarafis P. Comparison of Quality of Life before and after pancreaticoduodenectomy: a prospective study. Electron Physician 2018;10:7054-62. [PMID: 30128096 DOI: 10.19082/7054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
315 Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Mori M, Doki Y. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Ann Surg Oncol 2018;25:1868-79. [PMID: 29675761 DOI: 10.1245/s10434-018-6431-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
316 Wang L, Zhang B, Zheng W, Kang M, Chen Q, Qin W, Li C, Zhang Y, Shao Y, Wu Y. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 2017;7:5384. [PMID: 28710412 DOI: 10.1038/s41598-017-05541-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
317 Ray P, Ferraro M, Haag R, Quadir M. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer. Macromol Biosci 2019;19:e1900073. [PMID: 31183964 DOI: 10.1002/mabi.201900073] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
318 Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039-1047. [PMID: 25087471 DOI: 10.1016/j.ctrv.2014.07.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
319 Serri C, Quagliariello V, Iaffaioli RV, Fusco S, Botti G, Mayol L, Biondi M. Combination therapy for the treatment of pancreatic cancer through hyaluronic acid‐decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study. J Cell Physiol 2019;234:4959-69. [DOI: 10.1002/jcp.27297] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
320 Dhillon H, Chikara S, Reindl KM. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep 2014;1:309-18. [PMID: 25530945 DOI: 10.1016/j.toxrep.2014.05.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
321 Cox RE Jr, Mahipal A, Chakrabarti S. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus 2021;13:e14640. [PMID: 34055508 DOI: 10.7759/cureus.14640] [Reference Citation Analysis]
322 Feng HT, Zhao WW, Lu JJ, Wang YT, Chen XP. Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses adhesion, migration, and invasion of lung cancer A549 cells. Chin J Nat Med 2017;15:427-35. [PMID: 28629532 DOI: 10.1016/S1875-5364(17)30064-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
323 Peng F, Qin T, Wang M, Wang H, Dang C, Wu CH, Tien YW, Qin R. Development and Validation of a Nomogram to Predict Survival in Pancreatic Head Ductal Adenocarcinoma After Pancreaticoduodenectomy. Front Oncol 2021;11:734673. [PMID: 34660297 DOI: 10.3389/fonc.2021.734673] [Reference Citation Analysis]
324 Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65-88. [PMID: 23129367 DOI: 10.1007/978-3-642-31629-6_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
325 Wörmann SM, Algül H. Risk Factors and Therapeutic Targets in Pancreatic Cancer. Front Oncol 2013;3. [DOI: 10.3389/fonc.2013.00282] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
326 Xiong X, Shi Q, Yang X, Wang W, Tao J. LINC00052 functions as a tumor suppressor through negatively modulating miR‐330‐3p in pancreatic cancer. J Cell Physiol 2019;234:15619-26. [DOI: 10.1002/jcp.28209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
327 Cataldi M, Shah NR, Felt SA, Grdzelishvili VZ. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology. 2015;485:340-354. [PMID: 26331681 DOI: 10.1016/j.virol.2015.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
328 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
329 Xu XT, Chen J, Ren X, Ma YR, Wang X, Ma YY, Zhao DG, Zhou RP, Zhang K, Goodin S, Li DL, Zheng X. Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells. Eur J Pharmacol 2021;893:173840. [PMID: 33359649 DOI: 10.1016/j.ejphar.2020.173840] [Reference Citation Analysis]
330 Xin B, He X, Wang J, Cai J, Wei W, Zhang T, Shen X. Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. Pancreatology 2016;16:1005-14. [DOI: 10.1016/j.pan.2016.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
331 Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer. 2013;108:469-476. [PMID: 23169292 DOI: 10.1038/bjc.2012.495] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
332 Lian S, Zhai X, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. Medicine (Baltimore) 2016;95:e4328. [PMID: 27472713 DOI: 10.1097/MD.0000000000004328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
333 Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441. [PMID: 23222511 DOI: 10.1038/cddis.2012.181] [Cited by in Crossref: 215] [Cited by in F6Publishing: 194] [Article Influence: 21.5] [Reference Citation Analysis]
334 Adams MS, Scott SJ, Salgaonkar VA, Jones PD, Plata-Camargo JC, Sommer G, Diederich CJ. Development of an endoluminal high-intensity ultrasound applicator for image-guided thermal therapy of pancreatic tumors. Proc SPIE Int Soc Opt Eng 2015;9326:93260F. [PMID: 26677314 DOI: 10.1117/12.2078841] [Reference Citation Analysis]
335 Thomas ML, Marcato P. Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. Cancers (Basel) 2018;10:E101. [PMID: 29614786 DOI: 10.3390/cancers10040101] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
336 Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release 2015;214:76-84. [PMID: 26192099 DOI: 10.1016/j.jconrel.2015.07.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
337 Palzer J, Mues B, Goerg R, Aberle M, Rensen SS, Olde Damink SWM, Vaes RDW, Cramer T, Schmitz-Rode T, Neumann UP, Slabu I, Roeth AA. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids. Int J Nanomedicine 2021;16:2965-81. [PMID: 33935496 DOI: 10.2147/IJN.S288379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
338 Lee SH, Hao E, Kiselyuk A, Shapiro J, Shields DJ, Lowy A, Levine F, Itkin-Ansari P. The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma. Mol Cancer Res 2011;9:782-90. [PMID: 21498546 DOI: 10.1158/1541-7786.MCR-10-0535] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
339 Raja A, Malik MFA, Haq F. Genomic relevance of FGF14 and associated genes on the prognosis of pancreatic cancer. PLoS One 2021;16:e0252344. [PMID: 34061869 DOI: 10.1371/journal.pone.0252344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
340 Radke DI, Ungefroren H, Helm O, Voigt S, Alp G, Braun H, Hübner S, Dilchert J, Sebens S, Adam D, Kalthoff H, Trauzold A. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. Cell Signal 2016;28:1652-62. [PMID: 27492861 DOI: 10.1016/j.cellsig.2016.07.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
341 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 13.9] [Reference Citation Analysis]
342 Parker LA, Lumbreras B, Lopez T, Hernández-Aguado I, Porta M. How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis. Eur J Clin Invest 2011;41:793-805. [PMID: 21391995 DOI: 10.1111/j.1365-2362.2011.02495.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
343 Qian S, Tan X, Liu X, Liu P, Wu Y. Exosomal Tenascin-c induces proliferation and invasion of pancreatic cancer cells by WNT signaling. Onco Targets Ther 2019;12:3197-205. [PMID: 31118672 DOI: 10.2147/OTT.S192218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
344 Rao X, Wan L, Jie Z, Zhu X, Yin J, Cao H. Upregulated miR-27a-3p Indicates a Poor Prognosis in Pancreatic Carcinoma Patients and Promotes the Angiogenesis and Migration by Epigenetic Silencing of GATA6 and Activating VEGFA/VEGFR2 Signaling Pathway. Onco Targets Ther 2019;12:11241-54. [PMID: 31908490 DOI: 10.2147/OTT.S220621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
345 Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. JCO 2015;33:2028-34. [DOI: 10.1200/jco.2014.55.1481] [Cited by in Crossref: 146] [Cited by in F6Publishing: 71] [Article Influence: 20.9] [Reference Citation Analysis]
346 Aung W, Tsuji AB, Sudo H, Sugyo A, Furukawa T, Ukai Y, Kurosawa Y, Saga T. Immunotargeting of Integrin α6β4 for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model. Mol Imaging 2016;15:1536012115624917. [PMID: 27030400 DOI: 10.1177/1536012115624917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
347 Dai ZJ, Gao J, Ma XB, Kang HF, Wang BF, Lu WF, Lin S, Wang XJ, Wu WY. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci 2012;14:273-85. [PMID: 23344033 DOI: 10.3390/ijms14010273] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
348 Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin Cancer Res. 2014;20:1477-1488. [PMID: 24452790 DOI: 10.1158/1078-0432.ccr-13-2311] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
349 Mohammad J, Dhillon H, Chikara S, Mamidi S, Sreedasyam A, Chittem K, Orr M, Wilkinson JC, Reindl KM. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Oncotarget 2018;9:10457-69. [PMID: 29535819 DOI: 10.18632/oncotarget.23623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
350 Shi K, Queiroz KC, Roelofs JJ, van Noesel CJ, Richel DJ, Spek CA. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model: PAR-2 reduces metastasis in pancreatic cancer model. J Pathol 2014;234:398-409. [DOI: 10.1002/path.4411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
351 Stoof J, Harrold E, Mariottino S, Lowery MA, Walsh N. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front Cell Dev Biol 2021;9:749490. [PMID: 34712667 DOI: 10.3389/fcell.2021.749490] [Reference Citation Analysis]
352 Zhu Y, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e18581. [PMID: 32011436 DOI: 10.1097/md.0000000000018581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
353 Ji T, Lang J, Wang J, Cai R, Zhang Y, Qi F, Zhang L, Zhao X, Wu W, Hao J, Qin Z, Zhao Y, Nie G. Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy. ACS Nano 2017;11:8668-78. [PMID: 28806504 DOI: 10.1021/acsnano.7b01026] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 19.4] [Reference Citation Analysis]
354 Chen S, Huang J, Liu Z, Liang Q, Zhang N, Jin Y. FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogenesis 2017;6:e300. [PMID: 28287611 DOI: 10.1038/oncsis.2017.3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
355 Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang W, Zhang S, Wang Z. High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep 2015;5:12991. [PMID: 26259918 DOI: 10.1038/srep12991] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
356 Rybarczyk P, Vanlaeys A, Brassart B, Dhennin-Duthille I, Chatelain D, Sevestre H, Ouadid-Ahidouch H, Gautier M. The Transient Receptor Potential Melastatin 7 Channel Regulates Pancreatic Cancer Cell Invasion through the Hsp90α/uPA/MMP2 pathway. Neoplasia 2017;19:288-300. [PMID: 28284058 DOI: 10.1016/j.neo.2017.01.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
357 Martinez-Useros J, Georgiev-Hristov T, Borrero-Palacios A, Fernandez-Aceñero MJ, Rodríguez-Remírez M, Del Puerto-Nevado L, Cebrian A, Gomez Del Pulgar MT, Cazorla A, Vega-Bravo R, Perez N, Celdran A, Garcia-Foncillas J. Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant". Medicine (Baltimore) 2015;94:e1972. [PMID: 26559273 DOI: 10.1097/MD.0000000000001972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
358 Chen Q, Wang WJ, Jia YX, Yuan H, Wu PF, Ge WL, Meng LD, Huang XM, Shen P, Yang TY, Miao Y, Zhang JJ, Jiang KR. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci 2021;11:86. [PMID: 33985581 DOI: 10.1186/s13578-021-00602-8] [Reference Citation Analysis]
359 Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep 2016;16:133-47. [PMID: 27320920 DOI: 10.1016/j.celrep.2016.05.063] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
360 Su YY, Liu YS, Chao YJ, Chiang NJ, Yen CJ, Tsai HM. Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors. J Clin Med 2019;8:E1633. [PMID: 31590391 DOI: 10.3390/jcm8101633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Lei Y, Tang L, Xie Y, Xianyu Y, Zhang L, Wang P, Hamada Y, Jiang K, Zheng W, Jiang X. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat Commun 2017;8:15130. [PMID: 28440296 DOI: 10.1038/ncomms15130] [Cited by in Crossref: 152] [Cited by in F6Publishing: 134] [Article Influence: 30.4] [Reference Citation Analysis]
362 S D, L W, B GY, F YH, H SX, Q MZ, Hao C, W CQ, S LZ. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World J Surg Oncol 2017;15:120. [PMID: 28673297 DOI: 10.1186/s12957-017-1175-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
363 Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401. [PMID: 25250326 DOI: 10.1155/2014/678401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
364 Otto N, Schulz P, Scholz A, Hauff P, Schlegelberger B, Detjen KM, Wiedenmann B. The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. Br J Cancer 2012;106:348-57. [PMID: 22146521 DOI: 10.1038/bjc.2011.521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
365 Lv WF, Lu D, Xiao JK, Mukhiya G, Tan ZX, Cheng DL, Zhou CZ, Zhang XM, Zhang ZF, Hou CL. The side effects and complications of percutaneous iodine-125 seeds implantation under CT-guide for patients with advanced pancreatic cancer. Medicine (Baltimore) 2017;96:e9535. [PMID: 29384971 DOI: 10.1097/MD.0000000000009535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
366 Xia Y, Rocchi P, Iovanna JL, Peng L. Targeting heat shock response pathways to treat pancreatic cancer. Drug Discov Today 2012;17:35-43. [PMID: 21986108 DOI: 10.1016/j.drudis.2011.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
367 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
368 Sakai T, Mashima H, Yamada Y, Goto T, Sato W, Dohmen T, Kamada K, Yoshioka M, Uchinami H, Yamamoto Y, Ohnishi H. The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. Pancreas 2014;43:909-16. [PMID: 24632547 DOI: 10.1097/MPA.0000000000000116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
369 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117. [PMID: 20981102 DOI: 10.1038/nature09515,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
370 Wang L, Zhi X, Zhu Y, Zhang Q, Wang W, Li Z, Tang J, Wang J, Wei S, Li B, Zhou J, Jiang J, Yang L, Xu H, Xu Z. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC. Oncotarget 2015;6:33805-22. [PMID: 26393880 DOI: 10.18632/oncotarget.5668] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
371 Li L, Leung PS. Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol 2014;53:224-36. [PMID: 24875648 DOI: 10.1016/j.biocel.2014.05.021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
372 Wei X, He J, Gao B, Han L, Mao Y, Zhao H, Si N, Wang H, Yang J, Bian B. Hellebrigenin anti-pancreatic cancer effects based on apoptosis and autophage. PeerJ 2020;8:e9011. [PMID: 32426183 DOI: 10.7717/peerj.9011] [Reference Citation Analysis]
373 Lee SH, Jo JH, Kim YJ, Lee HS, Chung MJ, Park JY, Bang S, Park SW, Song SY. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Pancreas 2019;48:662-9. [PMID: 31091213 DOI: 10.1097/MPA.0000000000001319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
374 Guo W, Tan HY, Chen F, Wang N, Feng Y. Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines. Cancers (Basel) 2020;12:E404. [PMID: 32050640 DOI: 10.3390/cancers12020404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
375 Fredebohm J, Wolf J, Hoheisel JD, Boettcher M. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. J Cell Sci 2013;126:3380-9. [PMID: 23687379 DOI: 10.1242/jcs.124768] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
376 Radke DI, Ling Q, Häsler R, Alp G, Ungefroren H, Trauzold A. Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells. Cancers (Basel) 2018;10:E399. [PMID: 30366420 DOI: 10.3390/cancers10110399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
377 Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, Oupický D. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. ACS Nano 2020;14:255-71. [PMID: 31927946 DOI: 10.1021/acsnano.9b03978] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
378 Carlesso FN, Araújo RS, Fuscaldi LL, Mendes Miranda SE, Rubello D, Teixeira CS, dos Reis DC, Leite EA, Silveira JN, Fernandes SO, Cassali GD, de Oliveira MC, Colletti PM, de Barros AL, Cardoso VN. Preliminary data of the antipancreatic tumor efficacy and toxicity of long-circulating and pH-sensitive liposomes containing cisplatin. Nuclear Medicine Communications 2016;37:727-34. [DOI: 10.1097/mnm.0000000000000505] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
379 Long XY, Sun WJ, Zou YY, Li YX. Imaging evaluation of therapeutic response in patients with pancreatic cancer: recent advances. Shijie Huaren Xiaohua Zazhi 2011; 19(12): 1211-1218 [DOI: 10.11569/wcjd.v19.i12.1211] [Reference Citation Analysis]
380 He C, Huang X, Zhang Y, Lin X, Li S. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Pancreatology 2021;21:556-63. [PMID: 33518454 DOI: 10.1016/j.pan.2021.01.014] [Reference Citation Analysis]
381 Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. J Surg Oncol. 2012;105:655-661. [PMID: 22213144 DOI: 10.1002/jso.23020] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
382 Shi Y, He Z, Jia Z, Xu C. Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Mol Med Rep 2016;14:2921-8. [PMID: 27499118 DOI: 10.3892/mmr.2016.5592] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
383 Wang L, Zhang Y, Wang W, Zhu Y, Chen Y, Tian B. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). PLoS One 2017;12:e0184110. [PMID: 28854261 DOI: 10.1371/journal.pone.0184110] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
384 Lee S, N Srinivasa R, A Rigberg D, Yanagawa J, Benharash P, M Moriarty J. Aortoesophageal fistula involving the central aortic arch salvaged with emergent percutaneous TEVAR, great vessel coverage and in vivo graft fenestration. Diagn Interv Radiol 2021;27:122-5. [PMID: 33290236 DOI: 10.5152/dir.2020.20033] [Reference Citation Analysis]
385 Aldoss IT, Tashi T, Gonsalves W, Kalaiah RK, Fang X, Silberstein P, Ganti AK, Subbiah S. Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis. Journal of Geriatric Oncology 2011;2:209-14. [DOI: 10.1016/j.jgo.2011.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
386 Yang C, Wu Q, Huang K, Wang X, Yu T, Liao X, Huang J, Zhu G, Gong Y, Han C, Su H, Qin W, Peng T. Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma. Front Oncol 2019;9:511. [PMID: 31275849 DOI: 10.3389/fonc.2019.00511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
387 Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, de Angelis C, Granata V, Palaia R, Izzo F. Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients 2016;8:E433. [PMID: 27438851 DOI: 10.3390/nu8070433] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
388 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas. 2014;43:380-388. [PMID: 24622067 DOI: 10.1097/mpa.0000000000000097] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
390 Dasari T, Kondagari B, Dulapalli R, Abdelmonsef AH, Mukkera T, Padmarao LS, Malkhed V, Vuruputuri U. Design of novel lead molecules against RhoG protein as cancer target - a computational study. J Biomol Struct Dyn 2017;35:3119-39. [PMID: 27691842 DOI: 10.1080/07391102.2016.1244492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
391 Sharvit L, Bar-Shalom R, Azzam N, Yechiel Y, Wasser S, Fares F. Cyathus striatus Extract Induces Apoptosis in Human Pancreatic Cancer Cells and Inhibits Xenograft Tumor Growth In Vivo. Cancers (Basel) 2021;13:2017. [PMID: 33922003 DOI: 10.3390/cancers13092017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-503. [PMID: 21460848 DOI: 10.1038/nm.2344] [Cited by in Crossref: 885] [Cited by in F6Publishing: 764] [Article Influence: 80.5] [Reference Citation Analysis]
393 Hotz B, Erben U, Arndt M, Buhr HJ, Hotz HG. Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines. Int J Colorectal Dis. 2014;29:1339-1348. [PMID: 25179425 DOI: 10.1007/s00384-014-1998-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
394 Takai E, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 2015; 7(10): 250-258 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
395 Lu G, Shang W, Deng H, Han Z, Hu M, Liang X, Fang C, Zhu X, Fan Y, Tian J. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Biomaterials 2019;195:13-22. [DOI: 10.1016/j.biomaterials.2018.12.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
396 Hexige S, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, Lou W, Yu L. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol 2015;236:142-54. [PMID: 25561062 DOI: 10.1002/path.4506] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
397 Li PW, Luo S, Xiao LY, Tian BL, Wang L, Zhang ZR, Zeng YC. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability. Acta Pharmacol Sin 2019;40:1448-56. [PMID: 31015736 DOI: 10.1038/s41401-019-0227-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
398 Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020;5. [PMID: 31958291 DOI: 10.1136/esmoopen-2019-000587] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
399 Zou Q, Yang Z, Li D, Liu Z, Yuan Y. Association of chloride intracellular channel 4 and Indian hedgehog proteins with survival of patients with pancreatic ductal adenocarcinoma. Int J Exp Pathol. 2016;97:422-429. [PMID: 28205343 DOI: 10.1111/iep.12213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
400 Zhou J, Zhao R, Wen F, Zhang P, Tang R, Du Z, He X, Zhang J, Li Q. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0580-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
401 Mollinedo F, Gajate C. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers (Basel) 2021;13:4173. [PMID: 34439330 DOI: 10.3390/cancers13164173] [Reference Citation Analysis]
402 Kudo D, Suto A, Hakamada K. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2017;18:E600. [PMID: 28282922 DOI: 10.3390/ijms18030600] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
403 He X, Wang J, Wei W, Shi M, Xin B, Zhang T, Shen X. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. Cancer Biol Ther 2016;17:188-98. [PMID: 26785721 DOI: 10.1080/15384047.2016.1139228] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
404 Li Z, Lin P, Gao C, Peng C, Liu S, Gao H, Wang B, Wang J, Niu J, Niu W. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC). Tumour Biol 2016;37:5117-31. [PMID: 26547582 DOI: 10.1007/s13277-015-4353-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
405 Vila-Navarro E, Vila-Casadesús M, Moreira L, Duran-Sanchon S, Sinha R, Ginés À, Fernández-Esparrach G, Miquel R, Cuatrecasas M, Castells A, Lozano JJ, Gironella M. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. Ann Surg 2017;265:1226-34. [PMID: 27232245 DOI: 10.1097/SLA.0000000000001809] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
406 Wang FJ, Wang P, Chen LY, Geng YW, Chen H, Meng ZQ, Liu LM, Chen Z. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Integr Cancer Ther 2018;17:707-16. [PMID: 29681184 DOI: 10.1177/1534735418771193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
407 Kurahara H, Bohl C, Natsugoe S, Nishizono Y, Harihar S, Sharma R, Iwakuma T, Welch DR. Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 2016;139:628-38. [PMID: 27012470 DOI: 10.1002/ijc.30110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
408 Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo H, Tian T, Ruan ZP, Wei YC, Jiang LL. Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study. Oncotarget. 2016;7:9586-9599. [PMID: 26840020 DOI: 10.18632/oncotarget.7078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
409 Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013;32:5253-60. [PMID: 23416985 DOI: 10.1038/onc.2013.29] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 13.3] [Reference Citation Analysis]
410 Khushman M, Bhardwaj A, Patel GK, Laurini JA, Roveda K, Tan MC, Patton MC, Singh S, Taylor W, Singh AP. Exosomal Markers (CD63 and CD9) Expression Pattern Using Immunohistochemistry in Resected Malignant and Nonmalignant Pancreatic Specimens. Pancreas 2017;46:782-8. [PMID: 28609367 DOI: 10.1097/MPA.0000000000000847] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
411 Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther. 2012;11:2127-2137. [PMID: 22784710 DOI: 10.1158/1535-7163.mct-12-0342] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
412 Sun X, He X, Zhang Y, Hosaka K, Andersson P, Wu J, Wu J, Jing X, Du Q, Hui X, Ding B, Guo Z, Hong A, Liu X, Wang Y, Ji Q, Beyaert R, Yang Y, Li Q, Cao Y. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 2021:gutjnl-2020-322744. [PMID: 33568427 DOI: 10.1136/gutjnl-2020-322744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
413 Zhou Y, Wang K, Zhou Y, Li T, Yang M, Wang R, Chen Y, Cao M, Hu R. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling. Redox Biol 2020;29:101390. [PMID: 31785531 DOI: 10.1016/j.redox.2019.101390] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
414 Öman M, Wettergren Y, Odin E, Westermark S, Naredi P, Hemmingsson O, Taflin H. Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2021;88:619-31. [PMID: 34132895 DOI: 10.1007/s00280-021-04318-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
415 Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016;10:1169-1182. [PMID: 27282075 DOI: 10.1016/j.molonc.2016.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
416 Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A, Yen HY, Banerjee R, Louzada S, Fu B, Seidler B, Götzfried J, Schuck K, Hassan Z, Arbeiter A, Schönhuber N, Klein S, Veltkamp C, Friedrich M, Rad L, Barenboim M, Ziegenhain C, Hess J, Dovey OM, Eser S, Parekh S, Constantino-Casas F, de la Rosa J, Sierra MI, Fraga M, Mayerle J, Klöppel G, Cadiñanos J, Liu P, Vassiliou G, Weichert W, Steiger K, Enard W, Schmid RM, Yang F, Unger K, Schneider G, Varela I, Bradley A, Saur D, Rad R. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 2018;554:62-8. [PMID: 29364867 DOI: 10.1038/nature25459] [Cited by in Crossref: 164] [Cited by in F6Publishing: 139] [Article Influence: 41.0] [Reference Citation Analysis]
417 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
418 Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol 2018;118:1021-6. [PMID: 30259526 DOI: 10.1002/jso.25233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
419 Xie FJ, Zhao P, Zhang YP, Liu FY, Nie XL, Zhu YH, Yu XM, Zheng QQ, Mao WM, Lu HY. Adenovirus-mediated interferon-γ gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. Anat Rec (Hoboken). 2013;296:604-610. [PMID: 23401468 DOI: 10.1002/ar.22661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
420 Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, Wolfgang C, Herman J, Adsay VN, Hruban RH, Goggins M. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 2014;20:1865-72. [PMID: 24486587 DOI: 10.1158/1078-0432.CCR-13-1239] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 6.9] [Reference Citation Analysis]
421 Haas M, Laubender RP, Klose C, Schulz C, Mansmann U, Boeck S, Heinemann V. External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy. Pancreas 2012;41:738-44. [PMID: 22286380 DOI: 10.1097/MPA.0b013e31823bcc7b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
422 Tiriac H, Bucobo JC, Tzimas D, Grewel S, Lacomb JF, Rowehl LM, Nagula S, Wu M, Kim J, Sasson A, Vignesh S, Martello L, Munoz-Sagastibelza M, Somma J, Tuveson DA, Li E, Buscaglia JM. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc. 2018;87:1474-1480. [PMID: 29325707 DOI: 10.1016/j.gie.2017.12.032] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 15.8] [Reference Citation Analysis]
423 Fan G, Wan R, Zhang B, Deng S, Peng M, Xue W, Xu L, Qin X, Wu Y. The Distribution and Imaging of 99mTc-nGO-PEG-FA in Human Patu8988 Tumor-Bearing Nude Mice. Cancer Biother Radiopharm 2018;33:445-59. [PMID: 30133308 DOI: 10.1089/cbr.2017.2395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
424 Felt SA, Droby GN, Grdzelishvili VZ. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus. J Virol 2017;91:e00461-17. [PMID: 28566376 DOI: 10.1128/JVI.00461-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
425 Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Modjtahedi H. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer. 2013;13:41. [PMID: 23367880 DOI: 10.1186/1471-2407-13-41] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
426 Tingle SJ, Severs GR, Moir JAG, White SA. Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study. Anticancer Drugs 2020;31:737-41. [PMID: 32639282 DOI: 10.1097/CAD.0000000000000947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Hung SW, Mody HR, Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett. 2012;320:138-149. [PMID: 22425961 DOI: 10.1016/j.canlet.2012.03.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
428 Pelizzaro-Rocha KJ, de Jesus MB, Ruela-de-Sousa RR, Nakamura CV, Reis FS, de Fátima A, Ferreira-Halder CV. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. Biochim Biophys Acta 2013;1833:2856-65. [PMID: 23872419 DOI: 10.1016/j.bbamcr.2013.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
429 Ellenrieder V, Fernandez-Zapico ME. Transcriptional control of gene expression in pancreatic cancer: from sequence-specific transcription factors to nuclear architecture. J Gastrointest Cancer 2011;42:73-5. [PMID: 21279553 DOI: 10.1007/s12029-011-9254-4] [Reference Citation Analysis]
430 Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, Cunha AS, Vienot A, Lecomte T, Hautefeuille V, de La Fouchardière C, Sarabi M, Ksontini F, Forestier J, Coriat R, Fabiano E, Leroy F, Williet N, Bachet JB, Tougeron D, Taieb J. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer 2021;124:1941-8. [PMID: 33772154 DOI: 10.1038/s41416-021-01341-w] [Reference Citation Analysis]
431 Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2012;13:899-907. [PMID: 22785208 DOI: 10.4161/cbt.20842] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
432 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakagawa N, Takahashi S, Ohge H, Sueda T. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2017;79:775-81. [DOI: 10.1007/s00280-017-3274-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
433 Panebianco C, Adamberg K, Jaagura M, Copetti M, Fontana A, Adamberg S, Kolk K, Vilu R, Andriulli A, Pazienza V. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemother Pharmacol 2018;81:773-82. [DOI: 10.1007/s00280-018-3549-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
434 Kang SG, Zhou G, Yang P, Liu Y, Sun B, Huynh T, Meng H, Zhao L, Xing G, Chen C, Zhao Y, Zhou R. Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicine. Proc Natl Acad Sci U S A 2012;109:15431-6. [PMID: 22949663 DOI: 10.1073/pnas.1204600109] [Cited by in Crossref: 155] [Cited by in F6Publishing: 127] [Article Influence: 15.5] [Reference Citation Analysis]
435 Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. International Journal of Surgery 2016;34:96-102. [DOI: 10.1016/j.ijsu.2016.08.523] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
436 Fan YF, Shang WT, Lu GH, Guo KX, Deng H, Zhu XH, Wang CC, Tian J. Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer. Cancer Lett 2021;523:1-9. [PMID: 34530049 DOI: 10.1016/j.canlet.2021.09.016] [Reference Citation Analysis]
437 Ray P, Dutta D, Haque I, Nair G, Mohammed J, Parmer M, Kale N, Orr M, Jain P, Banerjee S, Reindl KM, Mallik S, Kambhampati S, Banerjee SK, Quadir M. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Mol Pharm 2021;18:87-100. [PMID: 33231464 DOI: 10.1021/acs.molpharmaceut.0c00499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
438 Sun Y, Gu M, Zhu L, Liu J, Xiong Y, Wei Y, Li F. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells. Anticancer Drugs 2016;27:183-91. [PMID: 26556627 DOI: 10.1097/CAD.0000000000000315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
439 Shen CQ, Yan TT, Liu W, Zhu XQ, Tian XL, Fu XL, Hua R, Zhang JF, Huo YM, Liu DJ, Yang JY, Sun YW, Fang JY, Chen HY, Hong J. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. J Cancer 2017;8:3154-65. [PMID: 29158787 DOI: 10.7150/jca.20086] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
440 Vila-Casadesús M, Vila-Navarro E, Raimondi G, Fillat C, Castells A, Lozano JJ, Gironella M. Deciphering microRNA targets in pancreatic cancer using miRComb R package. Oncotarget 2018;9:6499-517. [PMID: 29464088 DOI: 10.18632/oncotarget.24034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
441 Sun T, Peng H, Mao W, Ma L, Liu H, Mai J, Jiao L. Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer. Int J Biol Sci 2021;17:3634-45. [PMID: 34512171 DOI: 10.7150/ijbs.61795] [Reference Citation Analysis]
442 Zhu P, Liu HY, Liu FC, Gu FM, Yuan SX, Huang J, Pan ZY, Wang WJ. Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients. Cancer Control 2021;28:10732748211027163. [PMID: 34378430 DOI: 10.1177/10732748211027163] [Reference Citation Analysis]
443 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012;148:362-75. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 247] [Article Influence: 27.8] [Reference Citation Analysis]
444 Wang C, Liu P, Wu H, Cui P, Li Y, Liu Y, Liu Z, Gou S. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Oncotarget 2016;7:14912-24. [PMID: 26908446 DOI: 10.18632/oncotarget.7482] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
445 Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ, Wu WY. Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther 2013;7:149-59. [PMID: 23662044 DOI: 10.2147/DDDT.S42390] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
446 Zou W, Wang Z, Wang F, Zhang G, Liu R. A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study. BMC Cancer 2021;21:524. [PMID: 33964898 DOI: 10.1186/s12885-021-08250-4] [Reference Citation Analysis]
447 Huo Y, Yang M, Liu W, Yang J, Fu X, Liu D, Li J, Zhang J, Hua R, Sun Y. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2015;34:88. [PMID: 26297342 DOI: 10.1186/s13046-015-0202-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
448 Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2013;139:1117-1127. [PMID: 23546595 DOI: 10.1007/s00432-013-1422-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
449 Wang J, Xin B, Wang H, He X, Wei W, Zhang T, Shen X. Gastrin regulates ABCG2 to promote the migration, invasion and side populations in pancreatic cancer cells via activation of NF-κB signaling. Experimental Cell Research 2016;346:74-84. [DOI: 10.1016/j.yexcr.2016.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
450 Pelzer U, Arnold D, Reitzig P, Herrenberger J, Korsten FW, Kindler M, Stieler J, Dörken B, Riess H, Oettle H. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemother Pharmacol 2011;68:1173-8. [PMID: 21400239 DOI: 10.1007/s00280-011-1602-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
451 Sadanandam A, Sidhu SS, Wullschleger S, Singh S, Varney ML, Yang CS, Ashour AE, Batra SK, Singh RK. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer 2012;107:501-7. [PMID: 22782341 DOI: 10.1038/bjc.2012.298] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
452 Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 2017;23:1607-20. [PMID: 27637888 DOI: 10.1158/1078-0432.CCR-15-1615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
453 Adachi S, Yasuda I, Kawaguchi J, Yamauchi T, Nakashima M, Itani M, Nakamura M, Yoshioka T, Moriwaki H, Kozawa O. Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5’ AMP-activated protein kinase. Biochem Biophys Res Commun. 2011;414:53-59. [PMID: 21945432 DOI: 10.1016/j.bbrc.2011.09.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
454 Guo H, Liu F, Yang S, Xue T. Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression. Oncol Lett 2020;20:167. [PMID: 32934734 DOI: 10.3892/ol.2020.12030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
455 Fang Y, Han X, Li J, Kuang T, Lou W. HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer. J Oncol 2020;2020:3181596. [PMID: 32565799 DOI: 10.1155/2020/3181596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
456 Laval S, Laklai H, Fanjul M, Pucelle M, Laurell H, Billon-Galés A, Le Guellec S, Delisle MB, Sonnenberg A, Susini C. Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides. Oncogene. 2014;33:1934-1944. [PMID: 23624916 DOI: 10.1038/onc.2013.146] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
457 Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD, Sette C. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 2016;35:2031-9. [PMID: 26234680 DOI: 10.1038/onc.2015.270] [Cited by in Crossref: 89] [Cited by in F6Publishing: 102] [Article Influence: 12.7] [Reference Citation Analysis]
458 Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S, Chapelle J, Di Modugno F, Defilippi P, Nisticò P, Cappello P, Riganti C, Leporatti S, Novelli F. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol 2017;10:16. [PMID: 28086938 DOI: 10.1186/s13045-016-0385-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
459 Li H, Zhang Z, Gao C, Wu S, Duan Q, Wu H, Wang C, Shen Q, Yin T. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells. Cell Biosci 2019;9:50. [PMID: 31244991 DOI: 10.1186/s13578-019-0312-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
460 Zeleniak AE, Huang W, Fishel ML, Hill R. PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma. Neoplasia 2018;20:12-24. [PMID: 29175021 DOI: 10.1016/j.neo.2017.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
461 Lin S, Zhang J, Chen H, Chen K, Lai F, Luo J, Wang Z, Bu H, Zhang R, Li H, Tong H. Involvement of endoplasmic reticulum stress in capsaicin-induced apoptosis of human pancreatic cancer cells. Evid Based Complement Alternat Med 2013;2013:629750. [PMID: 23781265 DOI: 10.1155/2013/629750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
462 Sui K, Okabayashi T, Shima Y, Morita S, Iwata J, Sumiyoshi T, Saisaka Y, Hata Y, Noda Y, Matsumoto M, Nishioka A, Iiyama T, Shimada Y. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. Br J Radiol 2017;90:20170165. [PMID: 28590776 DOI: 10.1259/bjr.20170165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
463 Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178 [PMID: 26494971 DOI: 10.3748/wjg.v21.i39.11168] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
464 Garnier J, Ewald J, Marchese U, Gilabert M, Moureau-Zabotto L, Giovannini M, Poizat F, Delpero JR, Turrini O. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Eur J Surg Oncol 2020;46:1510-5. [PMID: 32146053 DOI: 10.1016/j.ejso.2020.02.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Lai M, Ge Y, Chen M, Sun S, Chen J, Cheng R. Saikosaponin D Inhibits Proliferation and Promotes Apoptosis Through Activation of MKK4-JNK Signaling Pathway in Pancreatic Cancer Cells. Onco Targets Ther 2020;13:9465-79. [PMID: 33061432 DOI: 10.2147/OTT.S263322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
466 Sauer BG, Shami VM. Survival in pancreatic cancer: the best is yet to come. Gastrointestinal Endoscopy 2010;72:84-5. [DOI: 10.1016/j.gie.2010.02.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
467 Hang J, Hu H, Huang J, Han T, Zhuo M, Zhou Y, Wang L, Wang Y, Jiao F, Wang L. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:28207-17. [PMID: 27057636 DOI: 10.18632/oncotarget.8593] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
468 Cui XG, Han ZT, He SH, Wu XD, Chen TR, Shao CH, Chen DL, Su N, Chen YM, Wang T, Wang J, Song DW, Yan WJ, Yang XH, Liu T, Wei HF, Xiao J. HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Oncotarget 2017;8:24840-52. [PMID: 28193910 DOI: 10.18632/oncotarget.15266] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
469 Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, Tang JH, Hou Y. Role of long non-coding RNA in tumor drug resistance. Tumour Biol 2016;37:11623-31. [PMID: 27380056 DOI: 10.1007/s13277-016-5125-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 8.7] [Reference Citation Analysis]
470 Mollinedo F, Gajate C. Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response. Ann Transl Med 2019;7:S153. [PMID: 31576360 DOI: 10.21037/atm.2019.06.40] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
471 Xiong C, Zhu Y, Xue M, Jiang Y, Zhong Y, Jiang L, Shi M, Chen H. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. Aging (Albany NY) 2021;13:3386-404. [PMID: 33428605 DOI: 10.18632/aging.202264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol 2014; 20(28): 9384-9391 [PMID: 25071333 DOI: 10.3748/wjg.v20.i28.9384] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
473 Zou Y, Han H, Ruan S, Jian Z, Jin L, Zhang Y, Chen Z, Yin Z, Ma Z, Jin H, Dai M, Shi N. Development of a Nomogram to Predict Disease-Specific Survival for Patients After Resection of a Non-Metastatic Adenocarcinoma of the Pancreatic Body and Tail. Front Oncol 2020;10:526602. [PMID: 33194585 DOI: 10.3389/fonc.2020.526602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
474 Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Gut Liver 2021;15:315-23. [PMID: 32235008 DOI: 10.5009/gnl19182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
475 Chen YW, Hsiao PJ, Weng CC, Kuo KK, Kuo TL, Wu DC, Hung WC, Cheng KH. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer. 2014;14:181. [PMID: 24625091 DOI: 10.1186/1471-2407-14-181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
476 Avery JT, Zhang R, Boohaker RJ. GLI1: A Therapeutic Target for Cancer. Front Oncol 2021;11:673154. [PMID: 34113570 DOI: 10.3389/fonc.2021.673154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Malleo G, Marchegiani G, Salvia R, Butturini G, Pederzoli P, Bassi C. Pancreaticoduodenectomy for pancreatic cancer: The Verona experience. Surg Today 2011;41:463-70. [DOI: 10.1007/s00595-010-4419-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
478 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci 2018;75:1001-12. [DOI: 10.1007/s00018-017-2678-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
479 Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 2017;36:1770-8. [PMID: 27669441 DOI: 10.1038/onc.2016.353] [Cited by in Crossref: 286] [Cited by in F6Publishing: 298] [Article Influence: 47.7] [Reference Citation Analysis]
480 Shi M, He X, Wei W, Wang J, Zhang T, Shen X. Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-κB pathway.Apoptosis. 2015;20:843-857. [PMID: 25690319 DOI: 10.1007/s10495-015-1106-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
481 Jadid MFS, Shademan B, Chavoshi R, Seyyedsani N, Aghaei E, Taheri E, Goleij P, Hajazimian S, Karamad V, Behroozi J, Sabet MN, Isazadeh A, Baradaran B. Enhanced anticancer potency of hydroxytyrosol and curcumin by PLGA-PAA nano-encapsulation on PANC-1 pancreatic cancer cell line. Environ Toxicol 2021;36:1043-51. [PMID: 33496383 DOI: 10.1002/tox.23103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
482 Rademaker G, Costanza B, Anania S, Agirman F, Maloujahmoum N, Di Valentin E, Goval JJ, Bellahcène A, Castronovo V, Peulen O. Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity through the Control of Oxidative Phosphorylation. Cancers (Basel) 2019;11:E853. [PMID: 31248212 DOI: 10.3390/cancers11060853] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
483 Lim JH, Park JS, Yoon DS. Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer. HPB 2017;19:388-95. [DOI: 10.1016/j.hpb.2016.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
484 Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2015;47:266-273. [PMID: 25327494 DOI: 10.4143/crt.2013.158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
485 Deng L, Shang Y, Guo S, Liu C, Zhou L, Sun Y, Nie Y, Fan D, Lu Y, Guo X. Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4. Cancer Biol Ther 2014;15:1087-93. [PMID: 24840182 DOI: 10.4161/cbt.29217] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
486 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117. [PMID: 20981102 DOI: 10.1038/nature09515] [Cited by in Crossref: 1664] [Cited by in F6Publishing: 1530] [Article Influence: 138.7] [Reference Citation Analysis]
487 Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rümmele P, Knösel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. EBioMedicine 2019;40:394-405. [PMID: 30709769 DOI: 10.1016/j.ebiom.2019.01.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
488 Jiang YJ, Lee CL, Wang Q, Zhou ZW, Yang F, Jin C, Fu DL. Establishment of an orthotopic pancreatic cancer mouse model: Cells suspended and injected in Matrigel. World J Gastroenterol 2014; 20(28): 9476-9485 [PMID: 25071342 DOI: 10.3748/wjg.v20.i28.9476] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
489 Sannino G, Armbruster N, Bodenhöfer M, Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B, Schmees C. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget 2016;7:73725-38. [PMID: 27713160 DOI: 10.18632/oncotarget.12455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
490 Takeda T, Izumi H, Kitada S, Uramoto H, Tasaki T, Zhi L, Guo X, Kawatsu Y, Kimura T, Horie S, Nabeshima A, Noguchi H, Wang KY, Sasaguri Y, Kohno K, Yamada S. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2014;35:10555-69. [PMID: 25060178 DOI: 10.1007/s13277-014-2328-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
491 Yang D, Shi J, Fu H, Wei Z, Xu J, Hu Z, Zhang Y, Yan R, Cai Q. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Tumour Biol 2016;37:12315-27. [PMID: 27289231 DOI: 10.1007/s13277-016-5061-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
492 Hu H, Gu Y, Qian Y, Hu B, Zhu C, Wang G, Li J. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. Biochem Biophys Res Commun. 2014;452:106-111. [PMID: 25152407 DOI: 10.1016/j.bbrc.2014.08.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
493 Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 2015;141:1653-60. [PMID: 25792009 DOI: 10.1007/s00432-015-1953-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
494 Hong Z, Wang Z, Zhou B, Wang J, Tong H, Liao Y, Zheng P, Jamshed MB, Zhang Q, Chen H. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells. Int J Oncol 2020;56:783-93. [PMID: 31922213 DOI: 10.3892/ijo.2020.4956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
495 Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol 2015;28:1383-9. [PMID: 26226846 DOI: 10.1038/modpathol.2015.89] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
496 Wang Y, Lin J, Cui J, Han T, Jiao F, Meng Z, Wang L. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. Oncotarget 2017;8:9354-65. [PMID: 28030840 DOI: 10.18632/oncotarget.14069] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
497 Yang F, Li X, Zhang L, Cheng L, Li X. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. J Pharmacol Sci 2018;137:116-21. [PMID: 29960845 DOI: 10.1016/j.jphs.2018.06.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
498 Zhong Y, Wang Z, Fu B, Pan F, Yachida S, Dhara M, Albesiano E, Li L, Naito Y, Vilardell F. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS One. 2011;6:e22129. [PMID: 21811562 DOI: 10.1371/journal.pone.0022129] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
499 Iacobuzio-Donahue CA. Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy. J Gastrointest Surg 2012;16:1651-2. [PMID: 22744639 DOI: 10.1007/s11605-012-1943-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
500 Adams MS, Salgaonkar VA, Plata-Camargo J, Jones PD, Pascal-Tenorio A, Chen HY, Bouley DM, Sommer G, Pauly KB, Diederich CJ. Endoluminal ultrasound applicators for MR-guided thermal ablation of pancreatic tumors: Preliminary design and evaluation in a porcine pancreas model. Med Phys 2016;43:4184. [PMID: 27370138 DOI: 10.1118/1.4953632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
501 Hu CY, Xu XM, Hong B, Wu ZG, Qian Y, Weng TH, Liu YZ, Tang TM, Wang MH, Yao HP. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer. Front Oncol. 2019;9:1377. [PMID: 31867280 DOI: 10.3389/fonc.2019.01377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
502 Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. BMC Cancer. 2015;15:71. [PMID: 25884642 DOI: 10.1186/s12885-015-1064-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
503 Wu Y, Gan Y, Yuan H, Wang Q, Fan Y, Li G, Zhang J, Yao M, Gu J, Tu H. Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents. Biochemical and Biophysical Research Communications 2016;473:593-9. [DOI: 10.1016/j.bbrc.2016.03.128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
504 Re TJ, Lemke A, Klauss M, Laun FB, Simon D, Grünberg K, Delorme S, Grenacher L, Manfredi R, Mucelli RP. Enhancing pancreatic adenocarcinoma delineation in diffusion derived intravoxel incoherent motion f-maps through automatic vessel and duct segmentation. Magn Reson Med. 2011;66:1327-1332. [PMID: 21437979 DOI: 10.1002/mrm.22931] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
505 Martinez-Useros J, Garcia-Foncillas J. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int 2016;2016:4873089. [PMID: 27689078 DOI: 10.1155/2016/4873089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
506 Sun Y, Zhang T, Wang C, Jin X, Jia C, Yu S, Chen J. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One. 2015;10:e0119783. [PMID: 25856297 DOI: 10.1371/journal.pone.0119783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
507 Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Itani M, Yoshioka T, Matsushima-Nishiwaki R, Hirose Y, Kozawa O, Moriwaki H. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett 2011;313:218-25. [PMID: 21999932 DOI: 10.1016/j.canlet.2011.09.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
508 Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One. 2012;7:e44146. [PMID: 22952903 DOI: 10.1371/journal.pone.0044146] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
509 Zhao Q, Huo XC, Sun FD, Dong RQ. Polyphenol-rich extract of Salvia chinensis exhibits anticancer activity in different cancer cell lines, and induces cell cycle arrest at the G₀/G₁-phase, apoptosis and loss of mitochondrial membrane potential in pancreatic cancer cells. Mol Med Rep 2015;12:4843-50. [PMID: 26165362 DOI: 10.3892/mmr.2015.4074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
510 Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, Nelson PJ, Ellwart JW, Bruns CJ, Camaj P. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol 2015;10:535-48. [PMID: 25639539 DOI: 10.1007/s11523-015-0360-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
511 Rah B, Banday MA, Bhat GR, Shah OJ, Jeelani H, Kawoosa F, Yousuf T, Afroze D. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer. World J Gastroenterol 2021; 27(36): 6093-6109 [PMID: 34629822 DOI: 10.3748/wjg.v27.i36.6093] [Reference Citation Analysis]
512 Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 2013;436:221-34. [PMID: 23246628 DOI: 10.1016/j.virol.2012.11.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis]
513 LaConti JJ, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT, Wellstein A. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One. 2011;6:e20687. [PMID: 21738581 DOI: 10.1371/journal.pone.0020687] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
514 Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines. Sci Rep 2020;10:3815. [PMID: 32123256 DOI: 10.1038/s41598-020-60765-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
515 Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opin Pharmacother 2019;20:535-46. [PMID: 30592647 DOI: 10.1080/14656566.2018.1561869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
516 Wang Z, Banerjee S, Ahmad A, Li Y, Azmi AS, Gunn JR, Kong D, Bao B, Ali S, Gao J, Mohammad RM, Miele L, Korc M, Sarkar FH. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One 2011;6:e20537. [PMID: 21673986 DOI: 10.1371/journal.pone.0020537] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
517 Li Z, Zou X, Zhu H, Chen M, Zhao Y. Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines. Oncol Lett 2018;15:5459-64. [PMID: 29552186 DOI: 10.3892/ol.2018.8043] [Reference Citation Analysis]
518 Yang Y, Wang Y, Liu S, Zhao X, Jia R, Xiao Y, Zhang M, Li X, Li J, Wang W. How hsa-miR-495 performed in the tumorigenesis of pancreatic adenocarcinoma by bioinformatics analysis. J Cell Biochem 2018. [PMID: 30485500 DOI: 10.1002/jcb.28055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Yang HS, Tamayo R, Almonte M, Horten B, DaSilva M, Gangi M, Vazquez E, Joseph D, Okamoto P, Scholl T. Clinical significance of MUC1, MUC2 and CK17 expression patterns for diagnosis of pancreatobiliary arcinoma. Biotech Histochem 2012;87:126-32. [PMID: 21438791 DOI: 10.3109/10520295.2011.570276] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]